

Supplementary Information

New conformationally flexible and recyclable aryl iodine catalysts from inexpensive chiral source for asymmetric oxidations

Table of Contents

1. Supplementary methods	3
2. Synthesis of the starting materials	4
3. Catalysts, solvent and temperature optimization	5
4. General procedure and spectra data of catalyst	9
4.1 General procedure for synthesis of catalyst starting from (1 <i>S</i> ,2 <i>S</i>)-ANP	9
4.1.1 General procedure for synthesis of intermediate 11	9
4.1.2 General procedure for synthesis of silicon-based catalysts	12
4.1.3 General procedure for synthesis of ester catalysts	13
4.1.4 General procedure for synthesis of ether catalysts	15
4.1.5 General procedure for synthesis of 2-iodo-5-substituted catalysts	16
4.2 Hundred grams scale procedure for synthesis of intermediate 11	17
4.3 General procedure for synthesis of catalyst starting from <i>D</i> -Threonine	18
4.4 General procedure for catalyst of the <i>N</i> -H bond of the amide moiety changed to <i>N</i> -Me bond	22
4.5 Characterization of catalysts and intermediates	22
5. General procedure of recycle experiments in oxidative dearomatization	48
6. Gram scale operation	50
7. Spectra data of substrate	51
7.1 Characterization of enantioselective oxidative dearomatization	51
7.2 Characterization of oxidative spiro lactonization	71
7.3 Characterization of direct C(sp ²)-H/C(sp ³)-H cross-coupling	77
7.4 Characterization of oxidative fluorination of keto esters	83
8. Investigation of the significance for H-bond interactions and tunable chiral pocket .	93
9. Reference	99
10. X-ray crystallography analysis	100

11. ¹H, ¹³C, ¹⁹F spectrum of compounds	105
11.1 NMR spectra of intermediates and catalyst	105
11.2 NMR spectra of product	154
11.2.1 Spectrum of enantioselective oxidative dearomatization	154
11.2.2 Spectrum of oxidative spirolactonization	179
11.2.3 Spectrum of direct C(sp ²)-H/C(sp ³)-H cross-coupling	185
11.2.4 Spectrum of oxidative fluorination of keto esters.....	191

1. Supplementary methods


General information. All experiments were conducted under air atmosphere unless otherwise noted. ^1H and ^{13}C NMR spectra were recorded on a Bruker AscendTM 400 (400 MHz) spectrometer. Chemical shifts were reported in parts per million (ppm), and the residual solvent peak was used as an internal reference: ^1H (CDCl_3 δ 7.26; DMSO-d^6 δ 2.50), ^{13}C (CDCl_3 δ 77.16; DMSO-d^6 δ 39.5). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad), coupling constants (Hz) and integration. For thin layer chromatography (TLC), Huanghai precoated TLC plates (GF254) were used, and compounds were visualized with a UV light at 254 nm. High resolution mass spectra (HRMS) were obtained on an Agilent 1290II-6545 spectrometer. Optical rotations were recorded on a Rudolph Research Analytical Autopol I automatic polarimeter. Enantiomeric excesses (*ee*) were determined by HPLC analysis on Agilent HPLC units; column of Chiralcel OD-H, Chiralpak AD-H or AS-H was used. Melting point (MP) was obtained on Hanon MP-430. Column chromatography was performed with silica gel (200-300 mesh ASTM). Unless otherwise noted, commercially available reagents purchased from Adamas-beta, TCI, Rhawn or Energy Chemical and were used as received.

2. Synthesis of the starting materials

- 1) General procedure for the synthesis of 1-naphthol carboxylic acid **12a-12l** were prepared according to the literature^[1].
- 2) General procedure for the synthesis of 2-naphthol carboxylic acid **12m-12o** were prepared according to the literature^[2].
- 3) General procedure for the synthesis of 1-naphthol carboxylic alcohol were prepared according to the literature^[3].
- 4) General procedure for the synthesis of 1-hydroxy-*N*-aryl-2-naphthamide **15a-15f** derivatives were prepared according to the literature^[4].
- 5) General procedure for the synthesis of anilide derivatives **17a-17f** derivatives were prepared according to the literature^[5].
- 6) General procedure for the synthesis of keto esters **19a-19k** derivatives were prepared according to the literature^[6].

3. Catalysts, solvent and temperature optimization

Supplementary Table 1. Optimization of enantioselective oxidative dearomatization^{a,b,c}




Entry	Cat (mol%)	Temp. (°C)	Solvent	Yield (%)	ee (%)	Entry	Cat (mol%)	Temp. (°C)	Solvent	Yield (%)	ee (%)
1	Cat-1 (15)	-30	CH ₂ Cl ₂	45	85	9	Cat-8 (15)	0	CH ₂ Cl ₂	87	96
2	Cat-2 (15)	-30	CH ₂ Cl ₂	66	79	10	Cat-33 (15)	0	CH ₂ Cl ₂	80	92
3	Cat-6 (15)	-30	CH ₂ Cl ₂	56	86	11	Cat-8 (15)	-20	toluene	77	96
4	Cat-8 (15)	-30	CH ₂ Cl ₂	77	98	12	Cat-8 (15)	-20	EtOAc	44	87
5	Cat-9 (15)	-30	CH ₂ Cl ₂	52	90	13	Cat-8 (15)	-20	CH ₂ Cl ₂ + EtOH ^d	92	98
6	Cat-11 (15)	-30	CH ₂ Cl ₂	47	86	14	Cat-8 (10) ^e	-20	CH ₂ Cl ₂ + EtOH ^d	80	98
7	Cat-21 (15)	-30	CH ₂ Cl ₂	35	75	15	Cat-8 (5) ^f	-20	CH ₂ Cl ₂ + EtOH ^d	72	98
8	Cat-8 (15)	-20	CH ₂ Cl ₂	82	98	16	Cat-8 (15)	-20	CH ₂ Cl ₂ + EtOH ^g	92	96

^a**12** (0.2 mmol), **Cat-8** (0.03 mmol, 15 mol%), *m*CPBA (0.3 mmol, 1.5 equiv.) were stirred in CH₂Cl₂ (10 mL) at -30 to 0 °C for 24 h. ^bIsolated yield. ^cThe *ee* value was determined by chiral HPLC. ^dEtOH (1 mmol, 5 equiv.) was added. ^e**Cat-8** (0.02 mmol, 10 mol%) was added. ^f**Cat-8** (0.01 mmol, 5 mol%) was added. ^gCH₂Cl₂ (5 mL), and EtOH (1 mmol, 5 equiv.) was added.

To a Schlenk tube containing **Cat-8**, *m*CPBA (0.3 mmol, 1.5 equiv.), and EtOH were added CH₂Cl₂ (10 mL) and **12** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 0 to -20 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by CH₂Cl₂ and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

Supplementary Table 2. Optimization of enantioselective oxidative spirolactonization^{a,b,c}




Entry	R ¹	R ²	R ³	T	Yield (%)	Time	ee (%)
1	Mes	COMes	H	-20 °C	30	2 day	56
2	Mes	COMes	Me	-20 °C	27	2 day	53
3	Mes	COMes	COOMe	-20 °C	33	2 day	55
4	Mes	COMes	3,5-di(CF ₃)C ₆ H ₃	-20 °C	25	2 day	53
5	Mes	TBDPS	H	-20 °C	35	2 day	70
6	Ad	TBDPS	H	-20 °C	39	2 day	96
7	4-OMeC ₆ H ₄	TBDPS	H	-20 °C	36	2 day	85
8	4-NO ₂ C ₆ H ₄	TBDPS	H	-20 °C	42	2 day	96
9	4-MeC ₆ H ₄	TBDPS	H	-20 °C	37	2 day	79
10	4- ^t BuC ₆ H ₄	TBDPS	H	-20 °C	40	2 day	87
11	4-NO ₂ C ₆ H ₄	TBDPS	H	-20 °C	55	5 day	91
12	4-NO ₂ C ₆ H ₄	TBDPS	H	0 °C	61	2 day	91
13	4-NO ₂ C ₆ H ₄	TBDPS	H	-10 °C	57	3 day	94

Conditions: ^a15 (0.2 mmol), **Cat-9** (0.03 mmol, 15 mol%), ^mCPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.) and H₂O (2 mmol, 10 equiv.) were stirred in MeNO₂ (3 mL) at -10 °C.

^cIsolated yield. ^dThe *ee* value was determined by chiral HPLC.

To a Schlenk tube containing **Cat-9** (0.03 mmol, 15 mol%), ^mCPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.), H₂O (2 mmol, 10 equiv.) and MeNO₂ (3 mL) were added **15** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at -10 °C for 72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by CH₂Cl₂ and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

Supplementary Table 3. Optimization of enantioselective direct C(sp²)-H/C(sp³)-H cross-coupling.^{a,b,c,d}




Entry	R ¹	R ²	R ³	Yield (%)	Solvent	ee (%)
1	Mes	COMes	H	23	MeCN	4
2	Mes	COMes	Me	27	MeCN	0
3	Mes	COMes	COOMe	35	MeCN	0
4	Mes	COMes	3,5-di(CF ₃)C ₆ H ₃	20	MeCN	0
5	Mes	TBDPS	H	60	MeCN	7
6	NH(4-Me)C ₆ H ₄	TBDPS	H	72	MeCN	74
7 ^b	NH(4-Me)C ₆ H ₄	TBDPS	H	N.R.	MeCN	00
8	NH(4-Me)C ₆ H ₄	TBDPS	H	42	Benzonitrile	50
9	NH(4-Me)C ₆ H ₄	TBDPS	H	37	Butyronitrile	83
10	4-MeC ₆ H ₄	TBDPS	H	40	Butyronitrile	84
11	4- ^t BuC ₆ H ₄	TBDPS	H	43	Butyronitrile	77
12	^t Bu	TBDPS	H	52	Butyronitrile	86
13	^t Bu	TBDPS	H	72	MeCN	84
14 ^c	^t Bu	TBDPS	H	72	MeCN	90

Conditions: ^a17 (0.2 mmol), **Cat-3** (0.03 mmol, 15 mol%), ^mCPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) were stirred in MeCN (3 mL) at 25 °C for 16 h. ^b0 °C. ^cAdd 3.0 equiv. H₂O. ^dIsolated yield. ^eThe ee value was determined by chiral HPLC.

To a Schlenk tube containing **Cat-3** (0.03 mmol, 15 mol%), ^mCPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) and H₂O and MeCN (3 mL) were added **17** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 25 °C for 16 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by EtOAc and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.

Supplementary Table 4. Optimization of enantioselective oxidative fluorination of keto esters.^{a,b,c,d}



Entry	R ¹	R ²	Yield (%)	ee (%)
1	H	COMes	55	44
2	2,6-diMe	COMes	57	61
3	3,5-diCF ₃	COMes	52	54
4	3,5-diCl	COMes	60	50
5	2,4,6-triMe	COMes	55	60
6	4-NO ₂	COMes	54	33
7	2,4,6-triCl	COMes	59	65
8 ^b	2,4,6-triCl	COMes	27	67
9	2,4,6-triBr	COMes	59	72
10	2,4,6-triCl	C(C ₆ H ₅) ₃	59	80
11	2,4,6-triBr	C(C ₆ H ₅) ₃	57	90


^a19 (0.2 mmol), **Cat-38** (0.03 mmol, 15 mol%), ^mCPBA (0.3 mmol, 1.5 equiv.), and Et₃N·3HF (2 mmol, 10 equiv.) were stirred in CHCl₃ (8 mL) at 25 °C for 24 h. ^bDPIEA·3HF (2 mmol, 10 equiv.) was added instead of Et₃N·3HF. ^cIsolated yield. ^dThe *ee* value was determined by chiral HPLC.

To a Teflon tube containing β -ketoesters **19** (0.20 mmol, 1.0 equiv.), **Cat-38** (0.03 mmol, 15 mol%), and CHCl₃ (8 mL) were added amine·HF (2 mmol, 10 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) in turn, the reaction mixture was stirred at 25 °C for 24-72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was extracted by CH₂Cl₂ and concentrated *in vacuo*. Purification by column chromatography afforded the desired product.


4. General procedure and spectra data of catalyst

4.1 General procedure for synthesis of catalyst starting from (1*S*,2*S*)-ANP.

4.1.1 General procedure for synthesis of intermediate 11



According to a modified literature procedure,^[7] to a 1-L round bottom flask containing (1*S*,2*S*)-ANP (330 mmol, 1.0 equiv.) were dissolved in THF (500 mL) at 0 °C, Boc_2O (346.5 mmol, 1.05 equiv.) was added dropwise and reaction mixture was allowed to stir at ambient temperature until full conversion of (1*S*,2*S*)-ANP, as shown by TLC. The organic layers were concentrated under vacuum. The crude product was recrystallized using ethyl acetate to afford the 6 (93.6 g, 91% yield) in a pure form.




According to a modified literature procedure,^[8] the cyclic sulfamidate was synthesized from the **6** by a three-step sequence: Silicon-based protection/Cyclization/NaIO₄ oxidation.

Step 1: the corresponding **6** (300 mmol, 1.0 equiv.) and imidazole (330 mmol, 1.3 equiv.) were dissolved in dry CH₂Cl₂ in a dry round bottom flask. TBDPSCl (315 mmol, 1.05 equiv.) dissolved in dry CH₂Cl₂ was added dropwise at 0 °C, and then the reaction mixture was allowed to stir at room temperature until TLC indicated completely consumed of the **6**. After completion of the reaction, water was added. The reaction mixture was extracted with CH₂Cl₂ (3x) and washed with brine (1x). The combined organic layers were dried over Na₂SO₄, the solvent was evaporated under vacuum. The crude residue was directly used in the next step without further purification.


Step 2: To the dry three-necked flask, the **7** (1.0 equiv.) and imidazole (3.0 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to -30 °C. Et₃N (2.4 equiv.) was added dropwise and the resulting mixture was stirred at -30 °C for 30 min. Then the SOCl₂ was added dropwise and the resulting mixture was stirred at -30 °C for 3 h until TLC indicated completely consumed of the **7**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 3: To the three-necked flask, **SI-1** was dissolved in MeCN and water (1:1), RuCl₃·3H₂O (1 mol%) and NaIO₄ (1.1 equiv.) were added sequentially and the resulting mixture was stirred at room temperature for 4 h until TLC indicated completely consumed of the **SI-1**. The MeCN was concentrated under vacuum. Water was added and the reaction mixture was extracted with ethyl acetate (3x). The organic layers were combined and dried over Na₂SO₄, filtered, and concentrated under

vacuum. The crude product is recrystallized using MeOH to afford the **10** (159 g, 86% yield in three steps) in a pure form.




To the dry three-necked flask tube, the **8** (1.0 equiv., 130 mmol, 30.68 g) was dissolved in dry DMF (300 mL) under nitrogen before being cooled to 0 °C. NaH (2.4 equiv., 312 mmol, 12.48 g) was added and the resulting mixture was stirred at 0 °C for 30 min. Then the **10** (2.0 equiv., 260 mmol, 159 g) dissolved in dry DMF (500 mL) was added dropwise and the resulting mixture was stirred at 0 °C for 4 h until TLC indicated completely consumption of the **9**. The reaction was quenched with 1N HCl. Water is further added to the system to precipitate the solids. Crude **Cat-1** (258 g) was isolated by filtration which was directly used in the next step without further purification.



To the dry three-necked flask, the crude **Cat-1** (258 g) was dissolved in dry CH₂Cl₂ (120 mL). TFA (30 mL) was dropwise at 0 °C and the resulting mixture was stirred at room temperature for 2 h until TLC indicated completely consumed of the **Cat-1**. The reaction was quenched with a saturated solution of NaHCO₃. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude product is recrystallized using MeOH to afford the **11** (106 g, 74% yield in two steps) in a pure form.

4.1.2 General procedure for synthesis of silicon-based catalysts




Method 1: To the dry three-necked flask, the aryl iodine intermediate **11** and Et₃N (2.3 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. R¹COCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated completely consumed of the aryl iodide. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding Chiral aryl iodine catalyst in a pure form.

Method 2: To the dry three-necked flask, the aryl iodide intermediates **11** and Et₃N (2.3 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. R²SO₂Cl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the aryl iodide. The reaction was quenched with water. The organic layer was separated and the aqueous layer was

extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding Chiral aryl iodine catalyst in a pure form.

Method 3: To the dry three-necked flask, the aryl iodide intermediates **11** and Et₃N (2.3 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. Isocyanates (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the aryl iodide. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding Chiral aryl iodine catalyst in a pure form.

4.1.3 General procedure for synthesis of ester catalysts




Step 1: To a round bottom flask containing the **Cat-1** (1.0 equiv.) and dry THF at room temperature was added TBAF (3.0 equiv.) dropwise. The reaction mixture was stirred for 3 h. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 2: To the dry three-necked flask, the **SI-2** and Et₃N (2.5 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. MesCOCl (2.2 equiv.) or AcCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the **SI-2**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding **SI-3** in a pure form.

Step 3: To the dry three-necked flask, the **SI-3** was dissolved in dry CH₂Cl₂. TFA was dropwise at 0 °C and the resulting mixture was stirred at room temperature for 2 h until TLC indicated completely consumed of the **SI-3**. The reaction was quenched with a saturated solution of NaHCO₃. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The residue was recrystallized using MeOH to afford the **SI-4** in a pure form.

The general procedure for synthesis of ester catalysts from **SI-4** is same to synthesis of silicon-based catalysts.


4.1.4 General procedure for synthesis of ether catalysts



Step 1: To a round bottom flask containing corresponding silicon-based catalysts (1.0 equiv.) and dry THF at room temperature was added TBAF (3.0 equiv.) dropwise. The reaction mixture was stirred for 3 h. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.


Step 2: To the dry three-necked flask, the **SI-5** and Et₃N (2.5 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to 0 °C. Ph₃CCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the **SI-5**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH₂Cl₂ (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was recrystallized using MeOH to afford the corresponding ether catalysts in a pure form.

4.1.5 General procedure for synthesis of 2-iodo-5-substituted catalysts




The general procedure was same to the procedure of synthesis of compound **11**.

4.2 Hundred grams scale procedure for synthesis of intermediate 11



Supplementary Figure 1. Flowchart of hundred grams scale synthesis of intermediate 11

4.3 General procedure for synthesis of catalyst starting from *D*-threonine




According to a modified literature procedure,^[9] **SI-4** was synthesized from the *D*-threonine by a three-step sequence: Esterification/Amino protection/ NaBH_4 reduction.

Step 1: To a 500-mL round bottom flask containing *D*-threonine (11.9 g, 100 mmol, 1.0 equiv.) and MeOH (200 mL) at 0 °C was added Thionyl chloride (150 mmol, 1.5 equiv.) dropwise. The reaction mixture was allowed to reflux overnight at 80 °C. The organic layers were concentrated under vacuum. The crude residue was directly used in the next step without further purification.


Step 2: The **SI-6** (1.0 equiv.) and NaHCO_3 (120 mmol, 1.2 equiv.) were dissolved in MeOH and water (1:1) before being cooled to 0 °C, Boc_2O (120 mmol, 1.2 equiv.) was added dropwise and the reaction mixture was allowed to stir at ambient temperature until full conversion of the **SI-6**, as shown by TLC. The MeOH was concentrated under vacuum. Water was added and the reaction mixture was extracted with CH_2Cl_2 (3x). The organic layers were combined and dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was directly used in the next step without further purification.

Step 3: To a 500-mL round bottom flask containing **SI-7** (1.0 equiv.) and MeOH at 0 °C was added NaBH_4 (300 mmol, 3.0 equiv.) portion wise. The reaction mixture was allowed to stir at 0 °C until TLC indicated full conversion of the **SI-7**. The

MeOH was concentrated under vacuum. Water was added and the reaction mixture was extracted with ethyl acetate (5x). The organic layers were combined and dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel (PE:EA 1:1) to afford the **SI-8** in a pure form. (15.4 g, 75% yield in three steps).




Step 4: The corresponding **SI-4** (15.4 g, 75 mmol, 1.0 equiv.) and imidazole (6.12 g, 90 mmol, 1.2 equiv.) were dissolved in dry CH₂Cl₂ in a dry round bottom flask. TBDPSCI (21.5 mL, 82.5 mmol, 1.1 equiv.) dissolved in dry CH₂Cl₂ was added dropwise at 0 °C, and then the reaction mixture was allowed to stir at room temperature until TLC indicated full conversion of the **SI-8**. After completion of the reaction, water was added. The reaction mixture was extracted with CH₂Cl₂ (3x) and washed with brine (1x). The combined organic layers were dried over Na₂SO₄, the solvent was evaporated under vacuum. The crude residue was directly used in the next step without further purification.




Step 5: According to a modified literature procedure,^[1] to the dry three-necked flask, the **SI-9** (1.0 equiv.) and imidazole (15.3 g, 225 mmol, 3.0 equiv.) were dissolved in dry CH₂Cl₂ under nitrogen before being cooled to -40 °C. Et₃N (25 mL, 180 mmol, 2.4 equiv.) was added dropwise and the resulting mixture was stirred at -40 °C for 30 min. Then the SOCl₂ (6.6 mL, 90 mmol, 1.2 equiv.) was added dropwise and the

chromatography on silica gel (PE:EA 6:1) to afford the **SI-12** (8.5 g, 78% yield) in a pure form.




Step 8: To the dry three-necked flask, the **SI-12** (8.5 g, 7.8 mmol, 1.0 equiv.) was dissolved in dry CH_2Cl_2 . TFA (10.0 equiv.) was added and the resulting mixture was stirred at room temperature for 2 h until TLC indicated consumption of the **SI-12**. The reaction was quenched with a saturated solution of NaHCO_3 . The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel (PE:EA 1:1) to afford the **SI-13** (6.6 g, 95% yield) in a pure form.




Step 9: To the dry three-necked flask, the **SI-13** and Et_3N (2.3 equiv.) were dissolved in dry CH_2Cl_2 under nitrogen before being cooled to 0 °C. R^1COCl (2.2 equiv.) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h until TLC indicated consumption of the **SI-13**. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with CH_2Cl_2 (3x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under vacuum. The crude residue was recrystallized by CH_2Cl_2 and hexane to afford the corresponding the **Catalyst** a pure form.

4.4 General procedure for catalyst of the *N*-H bond of the amide moiety changed to *N*-Me bond.




General procedure: To the dry three-necked flask tube, the corresponding *N*-H catalyst (1.0 equiv.) was dissolved in dry DMF under nitrogen before being cooled to 0°C. NaH (2.2 equiv.) was added and the resulting mixture was stirred at 0 °C for 30 min. Then the CH₃I (2.5 equiv.) was added dropwise and the resulting mixture was allowed to stirred at room temperature for 4 h until TLC indicated completely consumption of the starting material. The reaction was quenched with water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under vacuum. The crude residue was subjected to column chromatography on silica gel to afford the *N*-Me catalyst in a pure form.

4.5 Characterization of catalysts and intermediates.




9 was isolated from Mitsunobu reaction as colorless oil. DIAD (452 μ L, 2.3 mmol, 2.3 equiv.) was dropwise to **8** (236 mg, 1 mmol, 1 equiv.), **7** (550 mg, 2.2 mmol, 2.2 equiv.) and PPh₃ (707 mg, 2.7 mmol, 2.7 equiv.) in THF at 0 °C. **9** (316 mg, 27% yield) was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). (R_f = 0.6, petroleum ether/ethyl acetate = 5/1). ¹H NMR (400 MHz, CDCl₃) 7.97 (d, J = 8.9 Hz, 2H), 7.49 – 7.43 (m, 2H), 7.34 – 7.21 (m, 8H), 7.13 (dd, J = 8.9, 6.0 Hz, 2H), 3.69 – 3.60 (m, 2H), 3.07 (dd,

$J = 11.0, 7.6$ Hz, 1H), 3.03 – 2.96 (m, 1H), 1.38 (s, 9H), 0.87 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.6, 147.3, 142.2, 135.6, 135.3, 132.8, 132.7, 129.8, 129.8, 128.5, 127.7, 127.6, 123.3, 82.0, 60.9, 45.0, 42.4, 28.0, 27.9, 27.9, 26.7, 19.1. **HRMS** (ESI) m/z Calcd for $[\text{C}_{30}\text{H}_{36}\text{N}_2\text{O}_5\text{Si}, \text{M}+\text{Na}]^+$: 555.2286, found 555.2281.



The crude product is recrystallized using MeOH to afford the **10** (159 g, 86% yield in three steps) in a pure form. **MP**: 128.7-130.1 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.16-8.10 (m, 2H), 7.59 (m, 4H), 7.47-7.29 (m, 8H), 5.76 (d, $J = 5.7$ Hz, 1H), 4.16



(dd, $J = 10.3, 5.0$ Hz, 2H), 3.69-3.58 (m, 1H), 1.44 (s, 9H), 1.04 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 148.7, 148.2, 141.0, 135.7, 135.6, 132.4, 132.1, 130.4, 130.3, 128.2, 128.1, 128.0, 127.7, 124.3, 86.0, 79.1, 64.6, 59.6, 27.9, 26.8, 19.3. **HRMS** (ESI) m/z Calcd for $[\text{C}_{30}\text{H}_{36}\text{N}_2\text{O}_8\text{SSi}, \text{M}+\text{H}]^+$: 635.1854, found 635.1846.



The crude product is recrystallized using MeOH to afford the **11** (106 g, 74% in two steps) in a pure form. **MP**: 206.3-208.7 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, $J = 8.7$ Hz, 4H), 7.57-7.48 (m, 8H), 7.45-7.39 (m, 4H), 7.35-7.24 (m, 8H), 7.21-7.16 (m, 4H), 6.73 (t, $J = 8.3$ Hz, 1H),


5.97 (d, $J = 8.3$ Hz, 2H), 5.31 (d, $J = 5.8$ Hz, 2H), 3.88 (dd, $J = 10.2, 6.1$ Hz, 2H), 3.61 (dd, $J = 10.2, 5.0$ Hz, 2H), 3.37-3.28 (m, 2H), 0.96 (s, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.9, 147.8, 145.3, 135.7, 135.6, 133.1, 133.1, 130.0, 129.9, 129.7, 128.1, 128.0, 127.9, 123.9, 106.5, 80.9, 79.8, 64.9, 57.8, 27.0, 19.4. **HRMS** (ESI) m/z Calcd for $[\text{C}_{56}\text{H}_{61}\text{N}_4\text{O}_8\text{Si}_2, \text{M}+\text{H}]^+$: 1101.3145, found 1101.3154.

Optical Rotation: $[\alpha]_{\text{D}}^{25}$ 8.3 ($c = 1.0, \text{CHCl}_3$). >99.9% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_{\text{R}} = 5.180$ min for major isomer, $t_{\text{R}} = 8.713$ min for minor isomer).




SI-13 was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 5/1) as colorless oil. ($R_f = 0.5$, petroleum ether/ethyl acetate =

5/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.70-7.60 (m, 8H), 7.46-7.29 (m, 12H), 7.15 (t, $J = 8.3$ Hz, 1H), 6.44 (d, $J = 8.4$ Hz, 2H), 4.61-4.51 (m, 2H), 3.90-3.77 (m, 4H), 3.26-3.16 (m, 2H), 1.31 (d, $J = 6.3$ Hz, 6H), 1.06 (s, 18H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 157.8, 135.7, 135.7, 133.5, 133.4, 129.9, 129.8, 129.6, 127.9, 127.9, 106.1, 81.8, 76.2, 65.5, 56.7, 27.0, 19.4, 15.2. **HRMS** (ESI) m/z Calcd for $[\text{C}_{46}\text{H}_{59}\text{IN}_2\text{O}_4\text{Si}_2, \text{M}+\text{H}]^+$: 909.2950, found 909.2971.




The crude **Cat-1** was purified by MeOH and H_2O as yellow solid. **MP**: 108.0- 111.2°C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.15 (d, $J = 8.2$ Hz, 4H), 7.61-7.47 (m, 12H), 7.36 (dd, $J = 26.7, 7.3$ Hz, 8H), 7.21 (t, $J = 7.5$ Hz, 4H), 6.84 (t, $J = 8.2$

Hz, 1H), 6.05 (d, $J = 8.3$ Hz, 2H), 5.44 (d, $J = 6.3$ Hz, 2H), 5.01 (d, $J = 9.1$ Hz, 2H), 4.30 (dd, $J = 10.6, 5.1$ Hz, 2H), 4.22-4.17 (m, 2H), 3.89-3.79 (m, 2H), 1.32 (s, 18H), 1.03 (s, 18H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 157.1, 155.2, 147.7, 145.3, 135.6, 135.6, 132.9, 132.8, 130.0, 129.9, 129.7, 127.9, 127.9, 127.8, 123.8, 106.5, 79.9, 79.6, 79.5, 62.3, 57.1, 28.3, 27.0, 19.3. **HRMS** (ESI) m/z Calcd for $[\text{C}_{66}\text{H}_{77}\text{IN}_4\text{O}_{12}\text{Si}_2, \text{M}+\text{H}]^+$: 1323.4013, found 1323.4023.




Cat-2 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and acetyl chloride (173.8 mg, 2.2 mmol, 2.2 equiv.).

The crude residue was purified by MeOH to precipitate the title compound (1.086 g, 0.9 mmol, 90%) as a white solid. **MP**: 188.0-183.2 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.6 Hz, 4H), 7.50-7.45 (m, 8H), 7.41 (d, *J* = 8.5 Hz, 4H), 7.34-7.27 (m, 4H), 7.26-7.17 (m, 8H), 6.75 (t, *J* = 8.3 Hz, 1H), 5.95 (d, *J* = 8.4 Hz, 2H), 5.80 (d, *J* = 8.7 Hz, 2H), 5.38 (d, *J* = 5.4 Hz, 2H), 4.45-4.37 (m, 2H), 4.22 (dd, *J* = 11.0, 6.2 Hz, 2H), 3.72 (dd, *J* = 10.9, 3.3 Hz, 2H), 1.76 (s, 6H), 0.94 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 169.9, 157.2, 147.7, 144.9, 135.6, 132.9, 132.8, 130.1, 130.0, 130.0, 128.0, 128.0, 127.5, 123.9, 106.8, 79.7, 79.5, 61.8, 56.0, 26.9, 23.3, 19.3. **HRMS** (ESI) *m/z* Calcd for [C₆₀H₆₅IN₄O₁₀Si₂, M+H]⁺: 1207.3176, found 1207.3190.




Cat-3 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and pivaloyl chloride (265.3 mg, 2.2 mmol, 2.2 equiv.).

The crude residue was purified by MeOH and water to precipitate the title compound (1.078 g, 0.85 mmol, 85%) as a white solid. **MP**: 118.1-118.7 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.13 (d, *J* = 8.7 Hz, 4H), 7.57-7.48 (m, 12H), 7.41-7.37 (m, 2H), 7.36-7.28 (m, 6H), 7.25-7.19 (m, 4H), 6.84 (t, *J* = 8.3 Hz, 1H), 6.23 (d, *J* = 8.3 Hz, 2H), 6.06 (d, *J* = 8.4 Hz, 2H), 5.48 (d, *J* = 6.2 Hz, 2H), 4.54-4.45 (m, 2H), 4.35 (dd, *J* = 10.8, 5.4 Hz, 2H), 3.75 (dd, *J* = 10.8, 3.3 Hz, 2H), 1.03 (s, 18H), 1.02 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 178.2, 157.5, 147.8, 145.2, 135.6, 135.5, 132.7, 132.6, 130.1, 130.0, 130.0, 128.0, 128.0, 127.7, 123.8, 106.8, 79.5, 61.9, 55.7, 38.8, 27.5, 26.9, 19.3. **HRMS** (ESI) *m/z* Calcd for [C₆₆H₇₇IN₄O₁₀Si₂, M+H]⁺: 1269.4296, found 1269.4279.




Cat-4 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 1-adamantanecarbonyl chloride (437.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.331

g, 0.92 mmol, 92%) as a white solid. **MP**: 130.5-133.2 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.7 Hz, 4H), 7.59-7.50 (m, 12H), 7.48-7.27 (m, 8H), 7.26-7.20 (m, 4H), 6.86 (t, *J* = 8.3 Hz, 1H), 6.20 (d, *J* = 8.3 Hz, 2H), 6.07 (d, *J* = 8.4 Hz, 2H), 5.48 (d, *J* = 6.2 Hz, 2H), 4.56-4.46 (m, 2H), 4.38 (dd, *J* = 10.7, 5.4 Hz, 2H), 3.77 (dd, *J* = 10.7, 3.3 Hz, 2H), 1.98 (s, 6H), 1.75-1.57 (m, 24H), 1.03 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 177.7, 157.5, 147.7, 145.3, 135.6, 135.5, 132.7, 132.7, 130.1, 130.0, 129.9, 127.9, 127.9, 127.6, 123.7, 106.7, 79.5, 79.4, 62.0, 55.4, 40.6, 39.2, 36.4, 28.0, 26.9, 19.3. **HRMS** (ESI) *m/z* Calcd for [C₇₈H₈₉IN₄O₁₀Si₂, M+Na]⁺: 1447.5054, found 1447.5073.




Cat-5 was prepared using **SI-13** (886 mg, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and pivaloyl chloride (265.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified


by DCM and hexane to precipitate the title compound (970 mg, 0.92 mmol, 92%) as a white solid. **MP**: 67.2-67.8 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.68-7.63 (m, 4H), 7.56-7.51 (m, 4H), 7.46-7.41 (m, 2H), 7.41-7.33 (m, 6H), 7.29-7.23 (m, 4H), 7.18 (t, *J* = 8.3 Hz, 1H), 6.46 (d, *J* = 8.4 Hz, 2H), 6.21 (d, *J* = 8.6 Hz, 2H), 4.67 (p, *J* = 6.3 Hz, 2H), 4.38-4.23 (m, 4H), 3.87 (dd, *J* = 10.4, 3.4 Hz, 2H), 1.39 (d, *J* = 6.4 Hz, 6H), 1.17 (s, 18H), 1.04 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 178.2, 158.3, 135.6, 135.6, 133.0, 132.7, 130.0, 129.9, 127.9, 127.9, 105.9, 81.1, 74.8, 62.3, 54.6, 38.9, 27.6, 26.9, 19.3, 16.8. **HRMS** (ESI) *m/z* Calcd for [C₆₆H₇₇IN₄O₁₀Si₂, M+H]⁺: 1055.4281, found 1055.4306



Cat-6 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *p*-toluoyl chloride (339 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.096 g, 0.82 mmol, 82%) as a white solid. **MP**: 112.4-114.5 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.98 (d, *J* = 8.4 Hz, 4H), 7.51-7.40 (m, 16H), 7.31-7.24 (m, 4H), 7.21-7.12 (m, 12H), 6.71 (t, *J* = 8.3 Hz, 1H), 6.57 (d, *J* = 8.5 Hz, 2H), 5.94 (d, *J* = 8.4 Hz, 2H), 5.47 (d, *J* = 5.6 Hz, 2H), 4.69-4.59 (m, 2H), 4.34 (dd, *J* = 10.9, 6.1 Hz, 2H), 3.82 (dd, *J* = 10.9, 3.4 Hz, 2H), 2.30 (s, 6H), 0.91 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 167.0, 157.2, 147.7, 144.9, 142.5, 135.6, 135.5, 132.8, 132.7, 131.0, 130.0, 130.0, 129.4, 127.9, 127.4, 126.9, 123.9, 106.9, 80.0, 79.6, 61.9, 56.3, 26.9, 21.5, 19.2. **HRMS** (ESI) *m/z* Calcd for [C₇₂H₇₃IN₄O₁₀Si₂, M+Na]⁺: 1359.3802, found 1359.3774.




Cat-7 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-(trifluoromethyl)-benzoylchlorid (458.9 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.127 g, 0.78 mmol, 78%) as a white solid. **MP**: 120.3-121.5 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.02 (d, *J* = 8.7 Hz, 4H), 7.65-7.55 (m, 8H), 7.50-7.40 (m, 12H), 7.33-7.25 (m, 4H), 7.22-7.14 (m, 8H), 6.76 (t, *J* = 8.3 Hz, 1H), 6.58 (d, *J* = 8.5 Hz, 2H), 5.97 (d, *J* = 8.4 Hz, 2H), 5.48 (d, *J* = 5.5 Hz, 2H), 4.71-4.60 (m, 2H), 4.36 (dd, *J* = 11.0, 6.2 Hz, 2H), 3.83 (dd, *J* = 11.0, 3.4 Hz, 2H), 0.93 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.9, 157.2, 147.9, 144.6, 137.1, 135.6, 135.6, 133.6 (q, ²*J*_{C-F} = 32.7 Hz), 132.7, 132.7, 130.2, 130.1, 128.0, 128.0, 127.4, 125.8 (q, ³*J*_{C-F} = 3.7 Hz), 124.0, 123.7 (q, ¹*J*_{C-F} = 272.5 Hz), 107.1, 80.0, 79.5, 61.8, 56.5, 26.9, 19.3. **¹⁹F NMR** (376 MHz, CDCl₃) δ -62.86. **HRMS** (ESI) *m/z* Calcd for [C₇₂H₆₇F₆IN₄O₁₀Si₂, M+Na]⁺: 1445.3417, found 1445.3431.




Cat-8 was prepared using **SI-13** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH to precipitate the title compound (1.198 g, 0.86 mmol, 86%) as a white solid. **MP:** 205.0-207.3 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.09 (d, *J* = 8.8 Hz, 4H), 7.53-7.40 (m, 12H), 7.30-7.24 (m, 4H), 7.18-7.11 (m, 8H), 6.78 (t, *J* = 8.3 Hz, 1H), 6.73 (s, 4H), 6.02 (dd, *J* = 8.2, 2.3 Hz, 4H), 5.69 (d, *J* = 4.9 Hz, 2H), 4.71-4.59 (m, 2H), 4.30 (dd, *J* = 11.2, 6.8 Hz, 2H), 3.81 (dd, *J* = 11.1, 3.1 Hz, 2H), 2.22 (s, 6H), 1.88 (s, 12H), 0.94 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.7, 157.1, 147.9, 144.7, 138.9, 135.5, 134.2, 134.2, 132.7, 132.5, 130.1, 130.0, 129.9, 128.3, 127.9, 127.7, 124.0, 106.5, 79.5, 79.3, 61.7, 57.0, 26.9, 21.1, 19.2, 18.9. **HRMS** (ESI) *m/z* Calcd for [C₇₆H₈₁IN₄O₁₀Si₂, M+Na]⁺: 1415.4428, found 1415.4434.




Cat-9 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-nitrobenzoyl chloride (408.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.3 g, 0.93 mmol, 93%) as a white solid. **MP:** 130.5-132.7 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.5 Hz, 4H), 8.03 (d, *J* = 8.4 Hz, 4H), 7.64 (d, *J* = 8.6 Hz, 4H), 7.50-7.41 (m, 12H), 7.34-7.27 (m, 4H), 7.23-7.15 (m, 8H), 6.77 (t, *J* = 8.3 Hz, 1H), 6.60 (d, *J* = 8.5 Hz, 2H), 5.98 (d, *J* = 8.4 Hz, 2H), 5.49 (d, *J* = 5.5 Hz, 2H), 4.65 (dtd, *J* = 9.2, 5.9, 3.4 Hz, 2H), 4.37 (dd, *J* = 11.0, 6.3 Hz, 2H), 3.84 (dd, *J* = 11.1, 3.4 Hz, 2H), 0.92 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.2, 157.2, 149.8, 147.9, 144.4, 139.3, 135.6, 135.6, 132.6, 130.2, 130.1, 128.1, 128.1, 128.0, 127.4, 124.0, 123.9, 107.1, 79.9, 79.4, 61.7, 56.6, 26.9, 19.3. **HRMS** (ESI) *m/z* Calcd for [C₇₀H₆₇IN₆O₁₄Si₂, M+Na]⁺: 1421.3191, found 1421.3219.




Cat-10 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-methoxybenzoyl chloride (375.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.232 g, 0.90 mmol, 90%) as a white solid. **MP**: 80.1-

81.6 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.10 (d, *J* = 8.3 Hz, 4H), 7.61 (d, *J* = 8.4 Hz, 4H), 7.58-7.50 (m, 12H), 7.42-7.35 (m, 4H), 7.31-7.24 (m, 8H), 6.93 (d, *J* = 8.3 Hz, 4H), 6.80 (t, *J* = 8.3 Hz, 1H), 6.56 (d, *J* = 8.2 Hz, 2H), 6.02 (d, *J* = 8.3 Hz, 2H), 5.55 (d, *J* = 5.2 Hz, 2H), 4.76-4.66 (m, 2H), 4.42 (dd, *J* = 10.8, 6.0 Hz, 2H), 3.93-3.88 (m, 2H), 3.88 (s, 6H), 1.01 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 166.7, 162.6, 157.3, 147.7, 145.0, 135.7, 135.6, 132.9, 132.8, 130.1, 130.0, 128.8, 128.0, 127.4, 126.1, 124.0, 114.0, 107.0, 80.2, 79.6, 61.9, 56.4, 55.6, 26.9, 19.3. **HRMS** (ESI) *m/z* Calcd for [C₇₂H₇₃IN₄O₁₂Si₂, M+Na]⁺: 1421.3191, found 1421.3219.




Cat-11 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and benzoyl chloride (309.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.138 g, 0.87 mmol, 87%) as a white solid. **MP**: 161.3-162.5 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.8 Hz, 4H), 7.56-7.52 (m, 4H), 7.49-7.41 (m, 14H), 7.38-7.33 (m, 4H), 7.32-7.25 (m, 4H), 7.22-7.14 (m, 8H), 6.73 (t, *J* = 8.3 Hz, 1H), 6.55 (d, *J* = 8.5 Hz, 2H), 5.94 (d, *J* = 8.4 Hz, 2H), 5.47 (d, *J* = 5.5 Hz, 2H), 4.68-4.60 (m, 2H), 4.34 (dd, *J* = 10.9, 6.1 Hz, 2H), 3.81 (dd, *J* = 10.9, 3.4 Hz, 2H), 0.92 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 167.2, 157.3, 147.8, 144.9, 135.7, 135.6, 133.9, 132.8, 132.8, 132.0, 130.1, 130.1, 128.8, 128.0, 127.4, 127.0, 124.0, 107.0, 80.0, 79.6, 61.9, 56.4, 26.9, 19.3. **HRMS** (ESI) *m/z* Calcd for [C₇₀H₆₉IN₄O₁₀Si₂, M+H]⁺: 1309.3670, found 1309.3664.




Cat-12 was prepared using **SI-13** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude

residue was purified by CH₂Cl₂ and hexane to precipitate the title compound (1.138 g, 0.87 mmol, 87%) as a white solid. **MP**: 223.5-224.7 °C. **¹H NMR** (400 MHz, CDCl₃) δ 7.67 (d, *J* = 7.2 Hz, 4H), 7.58 (d, *J* = 7.3 Hz, 4H), 7.44 (t, *J* = 7.3 Hz, 2H), 7.36 (t, *J* = 7.4 Hz, 6H), 7.31-7.24 (m, 4H), 7.20 (t, *J* = 8.3 Hz, 1H), 6.85 (s, 4H), 6.47 (d, *J* = 8.4 Hz, 2H), 6.05 (d, *J* = 8.6 Hz, 2H), 4.84 (p, *J* = 6.1 Hz, 2H), 4.56 (m, 2H), 4.32 (dd, *J* = 10.8, 5.6 Hz, 2H), 4.06 (dd, *J* = 10.9, 3.6 Hz, 2H), 2.31 (s, 6H), 2.20 (s, 12H), 1.47 (d, *J* = 6.3 Hz, 6H), 1.06 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.6, 157.7, 138.6, 135.7, 135.6, 134.8, 134.2, 133.1, 132.8, 130.0, 129.9, 129.9, 128.4, 127.9, 127.9, 105.7, 74.3, 62.5, 55.6, 27.0, 21.2, 19.3, 19.2, 16.7. **HRMS** (ESI) *m/z* Calcd for [C₆₆H₇₉IN₂O₆Si₂, M+H]⁺: 1179.4600, found 1179.4610.




Cat-13 was prepared using **SI-13** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-nitrobenzoyl chloride (408.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by DCM and hexane to precipitate the title compound

(1.1 g, 0.93 mmol, 93%) as a white solid. **MP**: 107.4-109.8 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.25 (d, *J* = 8.6 Hz, 4H), 7.78 (d, *J* = 8.8 Hz, 4H), 7.66-7.53 (m, 8H), 7.48-7.32 (m, 8H), 7.30-7.24 (m, 4H), 7.17 (t, *J* = 8.3 Hz, 1H), 6.63-6.53 (m, 2H), 6.46 (d, *J* = 8.5 Hz, 2H), 4.77-4.69 (m, 2H), 4.59-4.49 (m, 2H), 4.38-4.27 (m, 2H), 4.14-4.04 (m, 2H), 1.44 (d, *J* = 6.6 Hz, 6H), 1.03 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.2, 158.1, 149.7, 140.0, 135.7, 135.7, 133.1, 132.8, 130.2, 130.1, 128.3, 128.1, 128.0, 123.9, 106.3, 81.2, 75.4, 62.2, 55.7, 27.0, 19.4, 16.9. **HRMS** (ESI) *m/z* Calcd for [C₆₀H₆₅IN₄O₁₀Si₂, M+Na]⁺: 1207.3176, found 1207.3190.



Cat-14 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *p*-Tolyl isocyanate (292.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.161 g, 0.85 mmol, 85%) as a white solid. **MP**: 181.1-182.3 °C.


¹H NMR (400 MHz, CDCl₃) δ 7.99 (d, *J* = 8.4 Hz, 4H), 7.43 – 7.37 (m, 8H), 7.34 (d, *J* = 7.4 Hz, 4H), 7.30 – 7.26 (m, 2H), 7.20 – 7.15 (m, 6H), 7.08 – 7.00 (m, 8H), 6.93 (d, 4H), 6.70 (t, *J* = 8.3 Hz, 1H), 6.52 (s, 2H), 5.92 (d, *J* = 8.4 Hz, 2H), 5.36 (d, *J* = 6.4 Hz, 2H), 5.27 (d, *J* = 8.5 Hz, 2H), 4.39 – 4.31 (m, 2H), 4.22 (dd, *J* = 10.7, 5.0 Hz, 2H), 3.68 (dd, *J* = 10.8, 3.2 Hz, 2H), 2.22 (s, 6H), 0.82 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 157.1, 155.7, 147.7, 145.4, 135.5, 135.5, 135.2, 134.9, 132.7, 132.6, 130.3, 130.0, 129.8, 127.9, 127.9, 127.8, 123.8, 123.3, 106.5, 79.3, 79.3, 62.3, 56.6, 26.8, 21.0, 19.2. **HRMS** (ESI) *m/z* Calcd for [C₇₂H₇₅IN₆O₁₀Si₂, M+H]⁺: 1367.4201, found 1367.4210.



Cat-15 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-(trifluoromethoxy)phenyl isocyanate (446.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH


and water to precipitate the title compound (1.161 g, 0.87 mmol, 87%) as a white solid. **MP**: 136.0-138.4 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.8 Hz, 4H), 7.58-7.53 (m, 8H), 7.48 (d, *J* = 8.9 Hz, 4H), 7.43-7.30 (m, 8H), 7.29-7.23 (m, 4H), 7.20-7.08 (m, 8H), 6.84 (t, *J* = 8.3 Hz, 1H), 6.53 (s, 2H), 6.05 (d, *J* = 8.4 Hz, 2H), 5.54 (d, *J* = 5.4 Hz, 2H), 5.19 (d, *J* = 8.0 Hz, 2H), 4.46-4.33 (m, 4H), 3.86 (dd, *J* = 10.6, 3.3 Hz, 2H), 0.99 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 157.1, 154.9, 147.7, 145.3, 145.0, 136.8, 135.6, 135.6, 132.9, 132.9, 130.2, 130.1, 128.0, 128.0, 127.6, 123.9, 122.2, 122.0, 120.5 (d, ¹*J*_{C-F} = 257.2 Hz), 106.8, 79.9, 79.3, 62.2, 57.1, 26.9,

19.3, 19.3. **¹⁹F NMR** (376 MHz, CDCl₃) δ -58.09. **HRMS** (ESI) m/z Calcd for [C₇₂H₆₉F₆IN₆O₁₂Si₂, M+H]⁺: 1529.3353, found 1529.3379.



Cat-16 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *o*-Tolyl isocyanate (292.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.190 g, 0.87 mmol, 87%) as a white solid. **MP**: 137.0-140.4 °C.


¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.6 Hz, 4H), 7.59-7.48 (m, 8H), 7.45-7.38 (m, 6H), 7.37-7.29 (m, 8H), 7.29-7.23 (m, 4H), 7.22-7.10 (m, 6H), 6.84 (t, *J* = 8.3 Hz, 1H), 6.59 (s, 2H), 6.06 (d, *J* = 8.4 Hz, 2H), 5.46 (d, *J* = 6.9 Hz, 2H), 5.26 (d, *J* = 8.6 Hz, 2H), 4.58-4.46 (m, 2H), 4.31 (dd, *J* = 10.6, 4.6 Hz, 2H), 3.79 (dd, *J* = 10.7, 3.2 Hz, 2H), 2.18 (s, 6H), 0.94 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 157.0, 156.0, 147.8, 145.5, 135.5, 135.4, 134.3, 132.6, 132.5, 131.5, 130.0, 129.8, 129.8, 127.9, 127.9, 127.8, 127.5, 127.2, 126.8, 123.7, 106.4, 79.3, 79.1, 62.2, 56.4, 26.8, 19.2, 18.0. **HRMS** (ESI) m/z Calcd for [C₇₂H₇₅IN₆O₁₀Si₂, M+H]⁺: 1367.4201, found 1367.4200.



Cat-17 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and *m*-Tolyl isocyanate (292.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.152 g, 0.83 mmol, 83%) as a white solid. **MP**: 139.0-142.8 °C.

¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.4 Hz, 4H), 7.56-7.47 (m, 12H), 7.40-7.35 (m, 2H), 7.35-7.26 (m, 6H), 7.23-7.15 (m, 6H), 7.00 (s, 2H), 6.95 (m, 4H), 6.82 (t, *J* = 8.3 Hz, 1H), 6.78 (s, 2H), 6.05 (d, *J* = 8.5 Hz, 2H), 5.53 (d, *J* = 6.0 Hz, 2H), 5.48 (d, *J* = 8.4 Hz, 2H), 4.53-4.45 (m, 2H), 4.35 (dd, *J* = 10.8, 5.4 Hz, 2H), 3.84 (dd, *J* = 10.9, 3.3 Hz, 2H), 2.30 (s, 6H), 0.96 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 157.1, 155.5, 147.6, 145.3, 139.6, 137.7, 135.5, 135.5, 132.8, 132.7, 130.0, 129.9,


129.4, 127.9, 127.9, 127.7, 125.7, 123.8, 123.0, 119.3, 106.5, 79.5, 79.2, 62.2, 56.7, 26.8, 21.5, 19.2. **HRMS** (ESI) m/z Calcd for $[C_{72}H_{75}IN_6O_{10}Si_2, M+Na]^+$: 1389.4020, found 1389.4021.



Cat-18 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and (Trifluoromethyl)benzene-1-sulfonylchloride (539 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by

MeOH to precipitate the title compound (1.322 g, 0.86 mmol, 86%) as a white solid.


MP: 116.3-119.7 °C. **1H NMR** (400 MHz, $CDCl_3$) δ 8.10 (d, $J = 8.3$ Hz, 4H), 7.77 (d, $J = 8.1$ Hz, 4H), 7.51 (d, $J = 8.2$ Hz, 4H), 7.46-7.37 (m, 14H), 7.33-7.23 (m, 6H), 7.16 (t, $J = 7.5$ Hz, 4H), 6.81 (t, $J = 8.3$ Hz, 1H), 5.99 (d, $J = 8.4$ Hz, 2H), 5.44 (d, $J = 6.2$ Hz, 2H), 5.28 (d, $J = 8.7$ Hz, 2H), 4.24 (dd, $J = 10.9, 4.7$ Hz, 2H), 3.81-3.76 (m, 2H), 3.59 (dd, $J = 11.0, 3.4$ Hz, 2H), 0.93 (s, 18H). **^{13}C NMR** (100 MHz, $CDCl_3$) δ 156.7, 148.0, 144.1, 143.9, 135.5, 134.5 (q, $^2J_{C-F} = 32.7$ Hz), 132.2, 132.2, 130.3, 130.1, 130.1, 128.0, 128.0, 127.8, 127.3, 126.3 (q, $^3J_{C-F} = 4.0$ Hz), 124.0, 123.1 (q, $^1J_{C-F} = 273.2$ Hz), 106.7, 79.2, 79.1, 61.7, 60.6, 26.9, 19.2. **^{19}F NMR** (376 MHz, $CDCl_3$) δ -66.13. **HRMS** (ESI) m/z Calcd for $[C_{70}H_{67}F_6IN_4O_{12}S_2Si_2, M+Na]^+$: 1539.2577, found 1539.2573.



Cat-19 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-tert-butylbenzenesulfonyl chloride (513 mg, 2.2 mmol, 2.2 equiv.). The crude residue was


purified by MeOH to precipitate the title compound (1.223 g, 0.82 mmol, 82%) as a white solid. **MP:** 128.3-130.4 °C. **1H NMR** (400 MHz, $CDCl_3$) δ 8.09 (d, $J = 8.6$ Hz, 4H), 7.57 (d, $J = 8.5$ Hz, 4H), 7.46 – 7.35 (m, 14H), 7.30 – 7.24 (m, 10H), 7.17 – 7.10

(m, 4H), 6.80 (t, $J = 8.3$ Hz, 1H), 6.01 (d, $J = 8.4$ Hz, 2H), 5.46 (d, $J = 6.5$ Hz, 2H), 5.24 (d, $J = 8.5$ Hz, 2H), 4.26 (dd, $J = 10.7, 4.4$ Hz, 2H), 3.76 – 3.68 (m, 2H), 3.65 (dd, $J = 10.8, 3.4$ Hz, 2H), 1.25 (s, 18H), 0.94 (s, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.8, 156.7, 147.9, 144.6, 137.1, 135.5, 135.4, 132.4, 130.1, 129.9, 127.9, 127.9, 126.8, 126.1, 123.9, 106.6, 79.3, 78.8, 61.8, 60.2, 35.1, 31.1, 26.9, 19.3. **HRMS** (ESI) m/z Calcd for $[\text{C}_{76}\text{H}_{85}\text{IN}_4\text{O}_{12}\text{S}_2\text{Si}_2, \text{M}+\text{Na}]^+$: 1515.4081, found 1515.4094.



Cat-20 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-tert-butylbenzenesulfonyl chloride (563 mg, 2.2 mmol, 2.2 equiv.). The crude residue was


purified by MeOH to precipitate the title compound (1.382 g, 0.9 mmol, 90%) as a white solid. **MP**: 116.2-118.4 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.10 (d, $J = 8.8$ Hz, 4H), 7.51-7.34 (m, 22H), 7.34-7.26 (m, 6H), 7.14 (t, $J = 7.6$ Hz, 4H), 6.82 (t, $J = 8.4$ Hz, 1H), 6.00 (d, $J = 8.5$ Hz, 2H), 5.41 (d, $J = 6.6$ Hz, 2H), 5.24 (d, $J = 8.8$ Hz, 2H), 4.24 (dd, $J = 10.8, 4.3$ Hz, 2H), 3.80-3.70 (m, 1H), 3.61 (dd, $J = 10.8, 3.4$ Hz, 2H), 0.95 (s, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.6, 147.9, 144.3, 139.3, 135.5, 135.4, 132.4, 132.2, 130.2, 130.1, 130.0, 128.3, 128.0, 127.9, 127.9, 124.0, 106.6, 79.3, 78.7, 61.8, 60.4, 26.9, 19.2. **HRMS** (ESI) m/z Calcd for $[\text{C}_{68}\text{H}_{67}\text{Br}_2\text{IN}_4\text{O}_{12}\text{S}_2\text{Si}_2, \text{M}+\text{Na}]^+$: 1559.1039, found 1559.1039.




Cat-21 was prepared using **11** (1.1 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and Tosyl chloride (419.4 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to

precipitate the title compound (1.324 g, 0.94 mmol, 94%) as a white solid. **MP**: 116.0-119.6 °C. ^1H NMR (400 MHz, CDCl_3) δ 7.86 (d, $J = 8.5$ Hz, 4H), 7.40-7.17 (m, 18H), 7.15-7.05 (m, 6H), 7.00-6.90 (m, 4H), 6.86 (d, $J = 8.1$ Hz, 4H), 6.64 (t, $J = 8.3$


Hz, 1H), 5.88 (d, $J = 8.5$ Hz, 2H), 5.39-5.21 (m, 4H), 4.16 (dd, $J = 10.6, 3.6$ Hz, 2H), 3.73-3.51 (m, 4H), 2.12 (s, 6H), 0.80 (s, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 156.5, 147.6, 144.7, 143.5, 137.2, 135.4, 135.3, 132.3, 129.9, 129.7, 129.5, 127.9, 127.8, 127.7, 126.7, 123.6, 106.4, 79.2, 78.1, 62.1, 60.1, 26.8, 21.3, 19.1. HRMS (ESI) m/z Calcd for $[\text{C}_{70}\text{H}_{73}\text{IN}_4\text{O}_{12}\text{S}_2\text{Si}_2, \text{M}+\text{H}]^+$: 1409.3322, found 1409.3314.




Cat-22 was prepared using **SI-13'** (886.3 mg, 1.0 mmol, 1.0 equiv.) starting from *L*-threonine, Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and mesitylcarbonylchloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was recrystallized by CH_2Cl_2 and hexane to yield the title compound as a white solid (1.013 g, 0.86 mmol, 86%).



Cat-23 was prepared using **SI-13'** (886.3 mg, 1.0 mmol, 1.0 equiv.) starting from *L*-threonine, Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and pivaloyl chloride (265.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was recrystallized by CH_2Cl_2 and hexane to yield the title compound as a white solid (0.78 g, 0.74 mmol, 74%).




Cat-24 was prepared using **11'** (1.1 g, 1.0 mmol, 1.0 equiv.) starting from (1*R*,2*R*)-ANP, Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound as a white solid (1.198 g, 0.86 mmol, 86%).



Cat-25 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-methoxybenzoyl chloride (375.3 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.1 g, 0.93 mmol, 93%) as a white solid. **MP:** 220.1-221.4 °C. **¹H NMR** (400 MHz, CDCl₃) δ


8.18 (d, *J* = 8.8 Hz, 4H), 7.78 (d, *J* = 8.9 Hz, 4H), 7.63 (d, *J* = 8.6 Hz, 4H), 7.08 (d, *J* = 7.9 Hz, 2H), 6.95 (d, *J* = 8.8 Hz, 4H), 6.85-6.81 (t, *J* = 8.3 Hz, 1H), 6.79 (s, 4H), 6.04 (d, *J* = 8.4 Hz, 2H), 5.72 (d, *J* = 3.6 Hz, 2H), 5.40-5.28 (m, 2H), 4.95-4.82 (m, 2H), 4.32 (dd, *J* = 11.9, 3.6 Hz, 2H), 3.87 (s, 6H), 2.25 (s, 6H), 2.16 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.7, 166.8, 162.8, 157.4, 147.9, 144.1, 140.0, 135.3, 130.3, 129.9, 129.0, 128.6, 127.1, 125.4, 124.3, 114.0, 107.4, 81.2, 79.4, 61.8, 55.6, 55.6, 21.2, 19.9. **HRMS** (ESI) *m/z* Calcd for [C₆₀H₅₇IN₄O₁₄, M+Na]⁺: 1207.2808, found 1207.2811.



Cat-26 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trichlorobenzoyl chloride (534.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.234 g, 0.93 mmol, 93%) as a white solid. **MP:** 170.4-173.9 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 4H),


7.64 (d, *J* = 8.8 Hz, 4H), 7.23 (s, 4H), 6.91 (t, *J* = 8.3 Hz, 1H), 6.79 (s, 6H), 6.15 (d, *J* = 8.4 Hz, 2H), 5.81 (d, *J* = 4.3 Hz, 2H), 5.07 (dd, *J* = 11.7, 7.3 Hz, 2H), 5.00-4.90 (m, 2H), 4.58 (dd, *J* = 11.8, 4.0 Hz, 2H), 2.26 (s, 6H), 2.17 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 169.7, 164.0, 156.9, 147.9, 143.8, 140.1, 136.4, 135.6, 133.4, 132.8, 129.4,

128.7, 128.2, 127.5, 124.2, 107.1, 79.9, 61.8, 54.9, 21.2, 20.2. **HRMS** (ESI) m/z Calcd for $[C_{58}H_{47}Cl_6IN_4O_{12}, M+Na]^+$: 1351.0259, found 1351.0238.



Cat-27 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 3,5-bis(trifluoromethyl)benzoyl chloride (609.4 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH and water to precipitate the title compound (1.234 g, 0.94


mmol, 94%) as a white solid. **MP**: 140.0-142.7 °C. **1H NMR** (400 MHz, $CDCl_3$) δ 8.28 (d, $J = 1.6$ Hz, 4H), 8.19 (d, $J = 8.8$ Hz, 4H), 8.05 (s, 2H), 7.67 (d, $J = 8.9$ Hz, 4H), 7.56 (d, $J = 8.0$ Hz, 2H), 6.90 (t, $J = 8.3$ Hz, 1H), 6.81 (s, 4H), 6.12 (d, $J = 8.5$ Hz, 2H), 5.76 (d, $J = 4.0$ Hz, 2H), 5.28 (dd, $J = 11.9, 8.6$ Hz, 2H), 5.03-4.94 (m, 2H), 4.45 (dd, $J = 12.0, 3.5$ Hz, 2H), 2.25 (s, 6H), 2.18 (s, 12H). **^{13}C NMR** (100 MHz, $CDCl_3$) δ 170.6, 164.5, 157.3, 148.1, 143.7, 140.3, 135.5, 135.5, 132.43 (q, $^2J_{C-F} = 34.2$ Hz), 130.5, 129.5, 128.8, 127.6, 127.6, 127.2, 125.7 (q, $^3J_{C-F} = 2.2$ Hz), 124.4, 122.9 (q, $^1J_{C-F} = 272.5$ Hz), 107.5, 80.8, 79.0, 61.9, 55.7, 21.1, 20.0. **^{19}F NMR** (376 MHz, $CDCl_3$) δ -62.83. **HRMS** (ESI) m/z Calcd for $[C_{62}H_{49}F_{12}IN_4O_{12}, M+Na]^+$: 1419.2092, found 1419.2098.



Cat-28 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 3,5-dichlorobenzoyl chloride (459.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH and water to precipitate the title compound (1.171 g, 0.93 mmol, 93%) as a


white solid. **MP**: 180.0-182.4 °C. **1H NMR** (400 MHz, $CDCl_3$) δ 8.21 (d, $J = 8.8$ Hz, 4H), 7.65 (d, $J = 8.6$ Hz, 8H), 7.53 (t, $J = 1.9$ Hz, 2H), 7.19 (d, $J = 8.0$ Hz, 2H), 6.87 (t, $J = 8.3$ Hz, 1H), 6.81 (s, 4H), 6.08 (d, $J = 8.5$ Hz, 2H), 5.69 (d, $J = 3.9$ Hz, 2H), 5.25 (dd, $J = 11.9, 8.8$ Hz, 2H), 4.94-4.83 (m, 2H), 4.38 (dd, $J = 11.9, 3.5$ Hz, 2H),

2.26 (s, 6H), 2.17 (s, 12H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 170.6, 164.8, 157.4, 148.1, 143.7, 140.2, 136.2, 135.8, 135.5, 132.2, 130.5, 129.7, 128.8, 127.2, 125.8, 124.4, 107.5, 80.9, 79.3, 61.8, 55.6, 21.2, 20.1. **HRMS** (ESI) m/z Calcd for $[\text{C}_{58}\text{H}_{49}\text{Cl}_4\text{IN}_4\text{O}_{12}, \text{M}+\text{H}]^+$: 1261.1219, found 1261.1220.



Cat-29 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-triBromobenzoyl chloride (600.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.271 g, 0.8 mmol, 80%) as a white solid. **MP**: 171.2-175.9 °C. $^1\text{H NMR}$ (400


MHz, CDCl_3) δ 8.21 (dd, $J = 9.0, 2.3$ Hz, 4H), 7.67-7.59 (m, 8H), 6.88 (t, $J = 8.3$ Hz, 1H), 6.80 (s, 4H), 6.57 (d, $J = 8.0$ Hz, 2H), 6.10 (d, $J = 8.4$ Hz, 2H), 5.83 (d, $J = 3.8$ Hz, 2H), 5.03-4.88 (m, 4H), 4.57 (dd, $J = 11.3, 3.6$ Hz, 2H), 2.27 (s, 6H), 2.20 (s, 12H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 169.7, 165.9, 157.0, 148.1, 143.7, 140.3, 137.7, 135.8, 134.5, 130.3, 129.5, 128.8, 127.4, 124.5, 124.4, 120.8, 107.3, 80.2, 80.1, 61.5, 54.8, 21.3, 20.5. **HRMS** (ESI) m/z Calcd for $[\text{C}_{58}\text{H}_{47}\text{Br}_6\text{IN}_4\text{O}_{12}, \text{M}+\text{Na}]^+$: 1614.7228, found 1614.7188.



Cat-30 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et_3N (232.3 mg, 2.3 mmol, 2.3 equiv.) and BzCl (310.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to


precipitate the title compound (0.9 g, 0.80 mmol, 80%) as a white solid. **MP**: 160.4-163.1 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.19 (d, $J = 8.8$ Hz, 4H), 7.82 (d, $J = 7.5$ Hz, 4H), 7.64 (d, $J = 8.8$ Hz, 4H), 7.57 (t, $J = 7.4$ Hz, 2H), 7.48 (t, $J = 7.7$ Hz, 4H), 7.16 (d, $J = 8.0$ Hz, 2H), 6.83 (t, $J = 8.3$ Hz, 1H), 6.79 (s, 4H), 6.04 (d, $J = 8.4$ Hz, 2H), 5.72 (d, $J = 3.8$ Hz, 2H), 5.34 (dd, $J = 11.9, 8.9$ Hz, 2H), 4.95-4.86 (m, 2H), 4.34 (dd, $J = 11.9, 3.6$ Hz, 2H), 2.25 (s, 6H), 2.16 (s, 12H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ

170.7, 167.3, 157.4, 148.0, 144.0, 140.1, 135.4, 133.2, 132.4, 130.4, 129.9, 129.0, 128.7, 127.2, 127.1, 124.4, 107.4, 81.1, 79.4, 61.8, 55.6, 21.2, 20.0. **HRMS** (ESI) m/z Calcd for $[C_{58}H_{53}IN_4O_{12}, M+Na]^+$: 1147.2597, found 1147.2590.




Cat-31 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title

compound (1.0 g, 0.83 mmol, 83%) as a white solid. **MP**: 164.0-167.0 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.18 (d, J = 8.5 Hz, 4H), 7.66 (d, J = 8.5 Hz, 4H), 6.94 (t, J = 8.4 Hz, 1H), 6.80 (d, J = 11.4 Hz, 8H), 6.45 (d, J = 8.6 Hz, 2H), 6.19 (d, J = 8.6 Hz, 2H), 5.78 (d, J = 4.9 Hz, 2H), 5.08-5.03 (m, 1H), 4.95 (dd, J = 11.7, 7.2 Hz, 2H), 4.63 (dd, J = 11.7, 3.2 Hz, 2H), 2.27 (s, 12H), 2.20 (s, 12H), 1.97 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.5, 169.4, 156.9, 147.8, 143.9, 139.9, 139.0, 135.3, 133.9, 133.7, 130.1, 129.6, 128.5, 128.3, 127.5, 124.0, 106.8, 79.9, 79.5, 62.2, 53.8, 21.1, 21.0, 20.0, 18.7. **HRMS** (ESI) m/z Calcd for $[C_{64}H_{65}IN_4O_{12}, M+H]^+$: 1209.3716, found 1209.3719.




Cat-32 was prepared using **SI-4-2** (0.708 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and acetyl chloride (173.8 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (0.665 g, 0.84 mmol, 84%) as a white solid. **MP**: 161.3-164.1 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.21 (d, J = 8.6 Hz, 4H), 7.57 (d, J = 8.6 Hz, 4H), 6.87 (t, J = 8.4 Hz, 1H), 6.30 (d, J = 8.0 Hz, 2H), 6.05 (d, J = 8.5 Hz, 2H), 5.54 (d, J = 3.3 Hz, 2H), 4.72-4.53 (m, 4H), 4.21-4.09 (m, 2H), 1.99 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.2, 170.4, 157.1, 147.9, 144.0, 130.3, 127.2, 124.3, 107.3, 80.8, 79.2, 61.6, 54.0, 23.5, 20.9. **HRMS** (ESI) m/z Calcd for $[C_{32}H_{33}IN_4O_{12}, M+H]^+$: 793.1212, found 793.1217.




Cat-33 was prepared using **SI-4-2** (0.708 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (0.920 g, 0.92 mmol,

92%) as a white solid. **MP:** 298.5-301.4 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.8 Hz, 4H), 7.64 (d, *J* = 8.8 Hz, 4H), 6.93 (t, *J* = 8.3 Hz, 1H), 6.83 (s, 4H), 6.35 (d, *J* = 8.3 Hz, 2H), 6.14 (d, *J* = 8.5 Hz, 2H), 5.78 (d, *J* = 3.8 Hz, 2H), 4.92-4.83 (m, 2H), 4.68 (dd, *J* = 11.9, 8.9 Hz, 2H), 4.24 (dd, *J* = 11.8, 3.6 Hz, 2H), 2.29 (s, 6H), 2.06 (s, 12H), 2.01 (s, 6H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.9, 157.1, 148.1, 143.7, 139.2, 134.1, 133.9, 130.5, 128.4, 127.4, 124.3, 106.9, 80.6, 79.4, 61.4, 54.2, 21.2, 20.8, 18.9. **HRMS** (ESI) *m/z* Calcd for [C₄₈H₄₉IN₄O₁₂, M+Na]⁺: 1023.2284, found 1043.2294.




Cat-34 was prepared using **SI-4-1** (0.916 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 4-nitrobenzoyl chloride (408.2 mg, 2.2 mmol, 2.2 equiv.). The crude residue was purified by MeOH to precipitate the title compound (1.130 g, 0.93 mmol, 93%) as a white solid. **MP:** 168.0-171.5 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.30-

8.24 (m, 4H), 8.20 (d, *J* = 8.9 Hz, 4H), 7.97 (d, *J* = 8.8 Hz, 4H), 7.65 (d, *J* = 8.8 Hz, 4H), 7.43 (dd, *J* = 8.0, 3.6 Hz, 2H), 6.88 (t, *J* = 8.3 Hz, 1H), 6.79 (s, 4H), 6.08 (dd, *J* = 8.4, 1.9 Hz, 2H), 5.73 (d, *J* = 3.9 Hz, 2H), 5.40 (dd, *J* = 12.0, 9.1 Hz, 2H), 4.95-4.86 (m, 1H), 4.41-4.33 (m, 2H), 2.24 (s, 6H), 2.14 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 171.0, 165.2, 157.3, 150.0, 148.1, 143.6, 140.3, 138.6, 135.3, 130.5, 129.5, 128.8, 128.4, 127.1, 124.5, 124.1, 107.6, 81.0, 79.4, 61.8, 56.0, 21.2, 20.0. **HRMS** (ESI) *m/z* Calcd for [C₅₈H₄₇Br₆IN₄O₁₂, M+H]⁺: 1209.3716, found 1209.3719.




Cat-35 was prepared using **SI-15-2** (0.974 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH and water to precipitate the title compound (1.126 g, 0.89 mmol, 89%) as a white solid. **MP:** 134.0-137.3 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.8 Hz, 4H), 7.67 (d, *J* = 8.8 Hz, 4H), 6.79 (d, *J* = 16.0 Hz, 10H), 6.22 (d, *J* = 8.6 Hz, 2H), 5.81 (d, *J* = 5.1 Hz, 2H), 5.06 (m, 2H), 4.94 (dd, *J* = 11.7, 6.6 Hz, 2H), 4.57 (dd, *J* = 11.8, 3.9 Hz, 2H), 3.73 (s, 3H), 2.26 (s, 6H), 2.26 (s, 6H), 2.17 (s, 12H), 1.94 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.6, 169.6, 165.2, 157.0, 148.2, 143.4, 140.2, 139.3, 135.4, 134.1, 133.7, 132.4, 129.7, 128.7, 128.5, 127.7, 124.4, 107.3, 86.1, 79.9, 62.3, 53.8, 52.8, 21.2, 21.2, 20.1, 18.9. **HRMS** (ESI) *m/z* Calcd for [C₆₆H₆₇IN₄O₁₄, M+Na]⁺: 1289.3591, found 1289.3595.




Cat-36 was prepared using **SI-15-1** (0.930 g, 1.0 mmol, 1.0 equiv.), Et₃N (232.3 mg, 2.3 mmol, 2.3 equiv.) and 2,4,6-trimethylbenzoyl chloride (401.6 mg, 2.2 mmol, 2.2 equiv.). The crude residue was

purified by MeOH and water to precipitate the title compound (1.038 g, 0.85 mmol, 85%) as a white solid. **MP:** 147.3-149.7 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.9 Hz, 4H), 7.66 (d, *J* = 8.8 Hz, 4H), 6.79 (d, *J* = 4.6 Hz, 8H), 6.29 (d, *J* = 8.4 Hz, 2H), 5.96 (s, 2H), 5.78 (d, *J* = 4.4 Hz, 2H), 4.98 (m, 2H), 4.89 (dd, *J* = 11.6, 7.5 Hz, 2H), 4.55 (dd, *J* = 11.6, 4.0 Hz, 2H), 2.28 (s, 6H), 2.26 (s, 6H), 2.18 (s, 12H), 2.00 (s, 3H), 1.97 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.7, 169.6, 156.8, 148.0, 144.1, 141.2, 140.1, 139.2, 135.5, 134.2, 133.8, 129.7, 128.6, 128.5, 128.5, 127.5, 124.3, 107.9, 79.9, 75.6, 62.1, 54.2, 21.9, 21.2, 21.2, 20.2, 18.9. **HRMS** (ESI) *m/z* Calcd for [C₆₅H₆₇IN₄O₁₂, M+Na]⁺: 1245.3692, found 1245.3704.




Cat-37 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.411 g, 0.92 mmol, 92%) as a white solid. **MP:** 159.3-162.4 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 4H), 7.53 (d, *J* = 8.8 Hz, 4H),

7.38-7.29 (m, 16H), 7.19 (dd, *J* = 5.1, 1.9 Hz, 18H), 6.86 (t, *J* = 8.3 Hz, 1H), 6.11 (t, *J* = 8.6 Hz, 4H), 5.76 (d, *J* = 4.6 Hz, 2H), 4.86-4.76 (m, 2H), 3.84 (dd, *J* = 10.4, 6.9 Hz, 2H), 3.48 (dd, *J* = 10.4, 3.5 Hz, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 163.9, 157.0, 147.9, 144.3, 143.4, 136.3, 133.9, 133.0, 130.2, 128.7, 128.3, 128.0, 127.7, 127.3, 124.1, 106.8, 87.4, 80.1, 79.8, 60.9, 55.8. **HRMS** (ESI) *m/z* Calcd for [C₇₆H₅₇Cl₆IN₄O₁₀, M+Na]⁺: 1543.0986, found 1543.0985.




Cat-38 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.462 g, 0.82 mmol, 82%) as a white solid. **MP:** 187.2-189.4 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.5 Hz, 4H), 7.66 (s, 4H), 7.52 (d, *J* =

8.8 Hz, 4H), 7.38-7.31 (m, 12H), 7.24-7.17 (m, 18H), 6.84 (t, *J* = 8.3 Hz, 1H), 6.18-6.02 (m, 3H), 5.82 (d, *J* = 3.8 Hz, 2H), 4.81-4.71 (m, 2H), 3.89-3.80 (m, 2H), 3.53 (dd, *J* = 10.4, 3.7 Hz, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 165.9, 157.0, 147.8, 144.2, 143.4, 138.1, 134.3, 130.1, 128.7, 128.0, 127.5, 127.3, 124.2, 124.1, 120.9, 106.8, 87.4, 80.3, 79.8, 60.7, 56.2. **HRMS** (ESI) *m/z* Calcd for [C₇₆H₅₅Br₆IN₄O₁₀, M+Na]⁺: 1806.7955, found 1806.7957.




Cat-39 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.462 g, 0.82 mmol, 82%) as a white solid. **MP:** 185.1-

187.3 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.07 (d, *J* = 8.5 Hz, 4H), 7.42 (dd, *J* = 16.3, 8.3 Hz, 8H), 7.31-7.24 (m, 12H), 7.17-6.98 (m, 20H), 6.73 (t, *J* = 8.3 Hz, 1H), 6.01 (dd, *J* = 24.5, 8.2 Hz, 4H), 5.77 (d, *J* = 3.9 Hz, 2H), 4.77-4.65 (m, 2H), 3.79-3.71 (m, 2H), 3.46 (dd, *J* = 10.5, 3.9 Hz, 2H). **¹³C NMR** (100 MHz, CDCl₃) δ 166.6, 156.9, 147.7, 144.4, 143.4, 139.1, 131.8, 131.7, 130.0, 128.7, 127.9, 127.4, 127.2, 124.0, 120.4, 106.8, 87.3, 80.4, 79.8, 60.7, 56.1. **HRMS** (ESI) *m/z* Calcd for [C₇₆H₅₇Br₄IN₄O₁₀, M+Na]⁺: 1650.9745, found 1650.9754.



Cat-40 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by MeOH to precipitate the title compound (1.148 g, 0.82 mmol, 82%) as a white solid. **MP:**


192.0-194.5 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.8 Hz, 4H), 7.51 (d, *J* = 8.8 Hz, 4H), 7.29-7.22 (m, 12H), 7.18-7.01 (m, 18H), 6.82 (t, *J* = 8.3 Hz, 1H), 6.73 (s, 4H), 6.09 (d, *J* = 8.5 Hz, 2H), 6.01 (d, *J* = 8.4 Hz, 2H), 5.75 (d, *J* = 4.9 Hz, 2H), 4.86-4.80 (m, 2H), 3.76 (dd, *J* = 10.2, 6.8 Hz, 2H), 3.41 (dd, *J* = 10.2, 3.4 Hz, 2H), 2.21 (s, 6H), 1.88 (s, 12H). **¹³C NMR** (100 MHz, CDCl₃) δ 170.5, 156.9, 147.8, 144.6, 143.3, 138.9, 134.2, 134.1, 130.1, 128.5, 128.3, 127.9, 127.7, 127.2, 123.9, 106.4, 87.2, 79.7, 79.7, 61.3, 55.3, 21.1, 18.9. **HRMS** (ESI) *m/z* Calcd for [C₈₂H₇₃IN₄O₁₀, M+Na]⁺: 1423.4264, found 1423.4256.



Cat-41 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 uL, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-8** (1.39 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel eluting with petroleum ether/ethyl acetate (5/1 to


2/1) to get **cat-41** (1.20 g, 83% yield) as a white solid. **MP:** 222.0- 125.4°C. **¹H NMR** (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.6 Hz, 4H), 7.58 (d, *J* = 7.0 Hz, 4H), 7.48 (dd, *J* = 12.7, 7.9 Hz, 8H), 7.41 (t, *J* = 7.4 Hz, 2H), 7.37-7.29 (m, 6H), 7.22 (t, *J* = 7.5 Hz, 4H),

6.86 (s, 2H), 6.82 (t, $J = 8.4$ Hz, 1H), 6.74 (s, 2H), 6.06 (d, $J = 8.4$ Hz, 2H), 5.90 (d, $J = 4.1$ Hz, 2H), 5.15-4.97 (m, 2H), 4.70-4.54 (m, 2H), 3.80 (dd, $J = 11.8, 3.3$ Hz, 2H), 3.09 (s, 6H), 2.27 (s, 6H), 2.20 (s, 6H), 1.69 (s, 6H), 0.99 (s, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 173.0, 156.9, 147.7, 144.7, 138.3, 135.6, 135.5, 133.9, 133.3, 133.2, 132.9, 132.4, 130.2, 129.9, 128.4, 128.3, 127.9, 127.8, 127.4, 124.0, 106.1, 80.0, 78.4, 60.9, 59.5, 33.4, 26.8, 21.2, 19.1, 19.0, 18.3. HRMS (ESI) m/z Calcd for $[\text{C}_{78}\text{H}_{85}\text{IN}_4\text{O}_{10}\text{Si}_2, \text{M}+\text{Na}]^+$: 1443.4741, found 1443.4813.




Cat-43 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH_3I (156 μL , 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-9** (1.42 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel eluting with petroleum ether/ethyl acetate (5/1 to

2/1) to get **Cat-43** [1.22 g, 86% yield. (The atropisomer ratio of **Cat-43** = 4:1 was detected by ^1H NMR in CDCl_3)] as a white solid. MP: 164.4- 167.3°C. ^1H NMR (400 MHz, CDCl_3) δ 8.27 (d, $J = 8.6$ Hz, 4H), 8.10 (d, $J = 8.5$ Hz, 4H), 7.66–7.54 (m, 8H), 7.51–7.38 (m, 16H), 7.30 (t, $J = 7.4$ Hz, 4H), 6.80 (t, $J = 8.4$ Hz, 1H), 5.98 (d, $J = 8.4$ Hz, 2H), 5.74 (d, $J = 5.0$ Hz, 2H), 4.84–4.58 (m, 4H), 4.04 (d, $J = 8.9$ Hz, 2H), 3.08 (s, 6H), 1.06 (s, 18H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.6, 156.6, 148.5, 147.9, 144.7, 142.4, 135.7, 135.6, 133.0, 132.5, 130.1, 128.0, 128.0, 127.9, 127.2, 124.1, 106.6, 79.7, 78.7, 64.8, 59.3, 36.7, 26.9, 19.3. HRMS (ESI) m/z Calcd for $[\text{C}_{72}\text{H}_{71}\text{IN}_6\text{O}_{14}\text{Si}_2, \text{M}+\text{H}]^+$: 1449.3504, found 1449.3537.




Supplementary Figure 2. Variable temperature NMR experiments of atropisomers **Cat-43** in DMSO- d^6




Cat-45 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 μ L, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-3** (1.27 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel

eluting with petroleum ether/ethyl acetate (10/1 to 3/1) to get **Cat-43** (583 mg, 45% yield) as a white solid. **MP**: 116.0-116.9 °C. **¹H NMR** (400 MHz, CDCl₃) δ 8.05 (d, J = 8.4 Hz, 4H), 7.74 – 7.22 (m, 24H), 6.71 (t, J = 8.3 Hz, 1H), 5.92 (d, J = 8.5 Hz, 2H), 5.66 (br s, 2H), 4.77 (br s, 2H), 4.57 (t, J = 10.6 Hz, 2H), 3.90 (br s, 2H), 3.26 (br s, 6H), 1.25 (s, 18H), 1.01 (s, 18H). **¹³C NMR** (100 MHz, CDCl₃) δ 178.7, 156.7, 147.5, 145.4, 135.5, 135.5, 133.1, 132.8, 129.8, 129.7, 129.6, 127.8, 127.2, 123.6, 106.2, 80.0, 78.6, 61.9, 59.2, 39.1, 28.0, 26.7, 19.1. **HRMS** (ESI) m/z Calcd for [C₆₈H₈₁IN₄O₁₀Si₂, M+K]⁺: 1335.4167, found 1335.4230.




Cat-47 was prepared following the procedure of synthesis of catalyst with N-Me amide moiety. CH₃I (156 uL, 2.5 mmol, 2.5 equiv.) was dropwise to **Cat-38** (1.78 g, 1.0 mmol, 1.0 equiv.) and NaH (88 mg, 2.2 mmol, 2.2 equiv.). The crude residue was isolated through silica gel eluting with petroleum ether/ethyl acetate

(5/1 to 2/1) to get **Cat-47** (1.59 g, 86% yield) as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, *J* = 8.8 Hz, 4H), 7.74 (d, *J* = 1.9 Hz, 2H), 7.62 (d, *J* = 1.9 Hz, 2H), 7.46 (d, *J* = 8.8 Hz, 4H), 7.34 (dd, *J* = 6.8, 3.1 Hz, 12H), 7.25-7.16 (m, 18H), 6.75 (t, *J* = 8.3 Hz, 1H), 5.95 (d, *J* = 8.5 Hz, 2H), 5.91 (s, 2H), 5.20-5.06 (m, 2H), 3.94 (t, *J* = 10.5 Hz, 2H), 3.51 (dd, *J* = 11.0, 3.5 Hz, 2H), 2.91 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 168.0, 156.6, 147.7, 144.4, 143.4, 138.2, 134.6, 134.2, 130.1, 128.6, 128.0, 127.3, 127.1, 124.1, 123.6, 120.6, 120.4, 106.1, 87.3, 80.3, 78.5, 60.1, 57.7, 33.1. HRMS (ESI) *m/z* Calcd for [C₇₈H₅₉Br₆IN₄O₁₀, M+Na]⁺: 1834.8268, found 1834.8277.



Cat-48 was prepared following the procedure of synthesis of ether catalyst. The crude residue was purified by DCM and hexane to precipitate the title compound as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, 4H), 7.41 (d, *J* = 6.8 Hz, 12H), 7.25 – 7.13 (m, 19H), 6.44 (d, *J* = 8.4 Hz, 2H), 5.98 (d, *J* = 8.6 Hz, 2H), 4.94 – 4.81 (m, 2H), 4.64 – 4.49 (m, 2H), 3.82 (dd, *J* = 10.1, 6.3 Hz, 2H), 3.62 (dd, *J* = 10.0, 3.4 Hz, 2H), 1.44 (d, *J* = 6.4 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 165.7, 157.7, 143.7, 138.6, 134.3, 129.9, 128.9, 128.0, 127.2, 123.8, 121.1, 105.9, 87.1, 82.1, 74.9, 61.5, 54.8, 16.9. HRMS (ESI) *m/z* Calcd for [C₆₆H₇₇Br₆IN₂O₆, M+Na]⁺: 1592.7941, found 1592.7988.



Cat-49 were prepared according to the literature^[2]. **¹H NMR** (400 MHz, CDCl₃)

δ 7.66 (s, 4H), 7.21 (t, *J* = 8.3 Hz, 1H),

6.54 (d, *J* = 8.3 Hz, 2H), 6.36 (t, *J* = 6.3 Hz, 2H), 4.70 (td, *J* = 6.9, 3.3 Hz, 2H), 3.94


(ddd, *J* = 14.0, 7.1, 3.3 Hz, 2H), 3.63–3.48 (m, 2H), 1.44 (d, *J* = 6.3 Hz, 6H). **¹³C**

NMR (100 MHz, CDCl₃) δ 166.0, 157.7, 138.7, 134.4, 130.3, 123.9, 121.0, 107.6,

82.9, 75.2, 44.9, 17.7. **HRMS** (ESI) *m/z* Calcd for [C₂₆H₂₁Br₆IN₂O₄, M+Na]⁺:

1048.5538, found 1048.5578.

5. General procedure of recycle experiments in oxidative dearomatization




Supplementary Figure 3. Catalyst recovery and recycle experiments in oxidative dearomatization.

General procedure: To a Schlenk tube containing **Cat-8** (417.2 mg, 0.3 mmol, 10 mol%), *m*CPBA (732.7 mg, 3.6 mmol, 1.2 equiv.) and EtOH (0.873 ml, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12a** (648 mg, 3 mmol, 1.0 equiv.). At the end of each reaction of the cycle, the reaction mixture was quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was then extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated in vacuo, the residue was subsequently dissolved by 30 mL of MeOH, H₂O (10 mL) was finally added to precipitate the catalyst which could enter the next cycle. The filtrate was concentrated in vacuo to get the crude product which could be further recrystallized by the mixture (10 mL, 1:300 volume ratio) of ethyl acetate and petroleum ether. After ten catalytic reactions, 320 mg of catalyst was obtained with a total recovery of 76.4%.

Supplementary Table 5. Data of recycle experiment.

yield of 13a	recovery yield of Cat-8	<i>ee</i> of 13a
87% (559 mg)	96% (402 mg)	97%
85% (545 mg)	97% (389 mg)	97%
84% (540 mg)	97% (377 mg)	97%
84% (539 mg)	97% (363 mg)	97%
83% (532 mg)	96% (350 mg)	97%
83% (532 mg)	98% (342 mg)	97%
83% (530 mg)	98% (335 mg)	97%
82% (527 mg)	99% (330 mg)	97%
82% (526 mg)	98% (325 mg)	97%
82% (526 mg)	98% (320 mg)	97%




Supplementary Figure 4. Comparison of recovered catalyst

6. Gram scale operation


To a Schlenk tube containing **Cat-8** (487.2 mg, 0.35 mmol, 5 mol%), *m*CPBA (1.718 g, 8.3 mmol, 1.2 equiv.) and EtOH (2.0 mL, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12a** (1.512 g, 7 mmol, 1.0 equiv.). And the reaction was stirred at -20 °C for 48 h. The reaction mixture was quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was then extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated in vacuo, the residue was subsequently dissolved by 70 mL of MeOH, H₂O (15 mL) was finally added to precipitate the catalyst (467 mg, 96% recovery yield). The product **13a** was obtained in 1.19g with 80% yield and 99% *ee* via recrystallization.

HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t*_R = 38.642 min for major isomer, *t*_R = 43.043 min for minor isomer




7. Spectra data of substrate.

7.1 Characterization of enantioselective oxidative dearomatization





General procedure: To a Schlenk tube containing **Cat-8** (0.03 mmol, 15 mol%), *m*CPBA (0.3 mmol, 1.5 equiv.), and EtOH (1 mmol, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 0 to -20 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the product **13**.



The reaction of 1-naphthol derivative **12a** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13a** (39.4 mg) in 92% yield as a white solid. The title compound **13a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R*_f = 0.5, petroleum ether/ethyl acetate = 3/1). **¹H NMR** (400 MHz, CDCl₃) δ 8.03 (d, *J* = 7.6 Hz, 1H), 7.65 (t, *J* = 7.4 Hz, 1H), 7.43 (t, *J* = 7.5 Hz, 1H), 7.29 (d, *J* = 7.6 Hz, 1H), 6.68 (d, *J* = 9.9 Hz, 1H), 6.23 (d, *J* = 9.9 Hz, 1H), 2.92 (ddd, *J* = 9.7, 11.2, 17.6 Hz, 1H), 2.62 (ddd, *J* = 2.0, 9.6, 17.6 Hz, 1H), 2.44 (ddd, *J* = 2.0, 9.6, 13.2 Hz, 1H), 2.22 (ddd, *J* = 9.8, 11.2, 13.2 Hz, 1H). **¹³C NMR** (100 MHz, CDCl₃) δ 196.7, 176.7, 136.9, 135.8, 132.3,

129.0, 128.1, 128.0, 127.8, 127.4, 83.6, 31.3, 26.6. **HRMS** (ESI) m/z Calcd for $[C_{13}H_{10}O_3, M + H]^+$: 215.0703; Found: 215.0701.



Optical Rotation: $[\alpha]_D^{25}$ 186.2 ($c = 1.0$, $CHCl_3$). 98% *ee* (HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 39.007$ min for major isomer, $t_R = 43.250$ min for minor isomer)



The reaction of 1-naphthol derivative **12b** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 24 h afforded compound **13a** (45.6 mg) in 92% yield as a white solid.

The title compound **13b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). **1H NMR** (400 MHz, $CDCl_3$) δ 8.03 (d, $J = 7.7$ Hz, 1H), 7.79-7.70 (m, 2H), 7.50 (m, 1H), 6.39 (s, 1H), 2.88 (ddd, $J = 17.6, 11.2, 9.5$ Hz, 1H), 2.61 (ddd, $J = 17.7, 9.6, 2.3$ Hz, 1H), 2.44 (ddd, $J = 13.5, 9.6, 2.3$ Hz, 1H), 2.24 (ddd, $J = 13.4, 11.1, 9.6$ Hz, 1H). **^{13}C NMR** (100 MHz, $CDCl_3$) δ 194.9, 176.0, 135.9, 134.6, 131.8, 130.2, 129.2, 128.1, 127.3, 126.2, 83.6, 31.5, 26.6. **HRMS** (ESI) m/z Calcd for $[C_{13}H_9ClO_3, M + H]^+$: 249.0313, 251.0289; Found: 249.0313, 251.0287.


Optical Rotation: $[\alpha]_D^{25}$ 101.1 ($c = 1.0$, $CHCl_3$). 98% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 23.793$ min for major isomer, $t_R = 30.546$ min for major isomer)




The reaction of 1-naphthol derivative **12c** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at 0 °C for 24 h afforded compound **13c** (49.5 mg) in 85% yield as a white solid. The title

compound **13c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 7.6 Hz, 1H), 7.73 (d, *J* = 4.0 Hz, 2H), 7.59-7.41 (m, 1H), 6.66 (s, 1H), 2.87 (ddd, *J* = 17.6, 11.1, 9.6 Hz, 1H), 2.61 (ddd, *J* = 17.6, 9.6, 2.4 Hz, 1H), 2.45 (ddd, *J* = 13.3, 9.5, 2.4 Hz, 1H), 2.36-2.11 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 194.9, 175.9, 136.0, 135.2, 133.5, 130.2, 128.9, 128.0, 127.4, 122.6, 84.4, 31.2, 26.5. HRMS (ESI) *m/z* Calcd for [C₁₃H₉O₃Br, M + H]⁺: 292.9808, 294.9793; Found: 292.9804, 294.9786.

Optical Rotation: [α]_D²⁵ 95.7 (*c* = 1.0, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 16.915 min for major isomer, *t_R* = 19.048 min for minor isomer).







The reaction of 1-naphthol derivative **12d** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13a** (58.7 mg) in 92% yield as a white solid. The title compound **13d**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 2/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 8.09 (dd, *J* = 7.8, 1.5 Hz, 1H), 8.02-7.88 (m, 2H), 7.66-7.56 (m, 2H), 7.53-7.42 (m, 3H), 7.39 (d, *J* = 7.8 Hz, 1H), 6.38 (s, 1H), 2.89 (ddd, *J* = 17.6, 11.3, 9.6 Hz, 1H), 2.60 (ddd, *J* = 17.6, 9.6, 2.2 Hz, 1H), 2.51 (ddd, *J* = 13.5, 9.5, 2.2 Hz, 1H), 2.28 (ddd, *J* = 13.4, 11.3, 9.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 195.4, 194.6, 176.0, 137.5, 136.1, 135.8, 134.4, 134.3, 134.2, 130.1, 129.9, 129.0, 128.5, 127.4, 127.0, 82.8, 31.2, 26.3. HRMS (ESI) *m/z* Calcd for [C₂₀H₁₄O₄, M + H]⁺: 319.0965; Found: 319.0964.

Optical Rotation: [α]_D²⁵ -36.8 (*c* = 1.0, CHCl₃). 85% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 30.062 min for major isomer, *t_R* = 36.179 min for minor isomer).





The reaction of 1-naphthol derivative **12e** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at 0 °C for 80 h afforded compound **13e** (36.2 mg) in 71% yield as a white solid. The title compound **13e** was

isolated through chromatography on silica gel eluting with petroleum ether/ethyl

acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.03 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 1H), 7.65 (td, $J = 7.7, 1.4$ Hz, 1H), 7.45 (t, $J = 7.6$ Hz, 1H), 6.82 (s, 1H), 2.83 (ddd, $J = 17.7, 11.4, 9.4$ Hz, 1H), 2.65-2.58 (m, 1H), 2.54 (s, 3H), 2.44 (ddd, $J = 13.7, 9.3, 2.1$ Hz, 1H), 2.28 (ddd, $J = 13.4, 11.5, 9.5$ Hz, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 199.1, 195.2, 175.8, 137.3, 137.0, 135.7, 133.2, 129.7, 128.4, 127.7, 127.5, 83.3, 31.1, 29.0, 26.2. **HRMS** (ESI) m/z Calcd for $[\text{C}_{15}\text{H}_{12}\text{O}_4, \text{M} + \text{H}]^+$: 257.0807; Found: 257.0808.



Optical Rotation: $[\alpha]_D^{25}$ 180.1 ($c = 1.0$, CHCl_3). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 30.95$ min for minor isomer, $t_R = 37.977$ min for major isomer).



The reaction of 1-naphthol derivative **12f** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 24 h afforded compound **13f** (34.8 mg) in 60% yield as a white solid. The title compound **13f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.09 (dd, $J = 7.7, 1.5$ Hz, 1H), 7.56 (td, $J = 7.7, 1.5$ Hz, 1H), 7.48-7.41 (m, 4H), 7.35 (dd, $J = 7.4, 2.2$ Hz, 2H), 7.16 (d, $J = 7.8$ Hz, 1H), 6.12 (s, 1H), 2.92 (ddd, $J = 17.6, 11.3, 9.6$ Hz, 1H), 2.63 (ddd, $J = 17.6, 9.6, 2.2$ Hz, 1H), 2.53 (ddd, $J = 13.4, 9.5, 2.2$ Hz, 1H), 2.28 (ddd, $J = 13.4, 11.3, 9.6$ Hz, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 196.6, 176.6, 140.0, 137.7, 137.5, 135.5, 130.7, 129.1, 128.9, 128.8,



128.6, 128.3, 127.7, 127.5, 83.9, 31.6, 26.9. **HRMS** (ESI) m/z Calcd for $[C_{19}H_{14}O_3, M + H]^+$: 291.1016; Found: 291.1015.

Optical Rotation: $[\alpha]_D^{25}$ 76 ($c = 0.2$, $CHCl_3$). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 18.103$ min for minor isomer, $t_R = 29.030$ min for major isomer).



The reaction of 1-naphthol derivative **12g** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 24 h afforded compound **13g** (48.6 mg) in 80% yield as a white solid. The title compound **13g** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.4$, petroleum ether/ethyl acetate = 3/1). 1H NMR (400 MHz, $CDCl_3$) δ 7.96 (d, $J = 7.7$ Hz, 1H), 7.51 (t, $J = 7.7$ Hz, 1H), 7.31 (dd, $J = 12.9, 7.2$ Hz, 2H), 7.24 (t, $J = 7.5$ Hz, 2H), 7.17 (d, $J = 7.5$ Hz, 3H), 5.82 (s, 1H), 3.81 (s, 2H), 2.79 (m, 1H), 2.48 (m, 1H), 2.36 (m, 1H), 2.18-2.03 (m, 1H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 196.7, 176.6, 137.5, 137.2, 135.9, 135.6, 130.9, 128.9, 128.9, 128.8, 128.1, 127.7, 126.9, 125.2, 83.8, 38.8, 31.6, 26.8. **HRMS** (ESI) m/z Calcd for $[C_{20}H_{16}O_3, M + H]^+$: 305.1172; Found: 305.1176.


Optical Rotation: $[\alpha]_D^{25}$ 104.2 ($c = 1$, $CHCl_3$). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 28.602$ min for major isomer, $t_R = 51.283$ min for minor isomer).




The reaction of 1-naphthol derivative **12h** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13h** (28.8 mg) in 63% yield as a white solid. The title compound **13h**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 7.6 Hz, 1H), 7.67 (td, *J* = 7.6, 1.6 Hz, 1H), 7.47-7.37 (m, 2H), 6.01 (s, 1H), 2.87 (ddd, *J* = 17.6, 11.2, 9.7 Hz, 1H), 2.57 (ddd, *J* = 17.6, 9.5, 1.9 Hz, 1H), 2.39 (ddd, *J* = 13.5, 9.6, 2.3 Hz, 1H), 2.18 (s, 3H), 2.22-2.08 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 196.9, 176.8, 138.0, 135.7, 133.2, 129.0, 128.8, 127.9, 127.4, 125.0, 83.7, 31.6, 26.9, 19.4. HRMS (ESI) *m/z* Calcd for [C₁₄H₁₂O₃, M + H]⁺: 229.0859; Found: 229.0861.

Optical Rotation: [α]_D²⁵ 104.2 (*c* = 1, CHCl₃). 93% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 20.420 min for minor isomer, *t_R* = 23.698 min for major isomer).







The reaction of 1-naphthol derivative **12i** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13i** (32.4 mg) in 92% yield as a white solid. The title compound **13i**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (dd, *J* = 7.7, 0.9 Hz, 1H), 7.66 (td, *J* = 7.8, 1.2 Hz, 1H), 7.45 (d, *J* = 7.9 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 5.98 (s, 1H), 2.86 (ddd, *J* = 17.6, 11.3, 9.6 Hz, 1H), 2.62-2.52 (m, 3H), 2.39 (ddd, *J* = 13.2, 9.5, 1.9 Hz, 1H), 2.16 (ddd, *J* = 13.4, 11.4, 9.6 Hz, 1H), 1.23 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 197.0, 176.7, 138.3, 137.5, 135.6, 128.6, 128.1, 127.6, 127.2, 124.4, 83.9, 31.6, 26.9, 25.1, 12.4. HRMS (ESI) *m/z* Calcd for [C₁₅H₁₄O₃, M + H]⁺: 243.1016; Found: 243.1016.

Optical Rotation: [α]_D²⁵ 176.6 (*c* = 1, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 18.914 min for minor isomer, *t_R* = 20.283 min for major isomer).





The reaction of 1-naphthol derivative **12j** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13j** (32.2 mg) in 63% yield as a white solid. The title compound **13j**

was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.4, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.65 (td, *J* = 7.6, 1.5 Hz, 1H), 7.46-



7.34 (m, 2H), 5.97 (s 1H), 2.85 (ddd, $J = 17.6, 11.4, 9.5$ Hz, 1H), 2.63-2.53 (m, 1H), 2.55-2.45 (m, 2H), 2.39 (ddd, $J = 13.5, 9.5, 2.1$ Hz, 1H), 2.15 (ddd, $J = 13.5, 11.4, 9.5$ Hz, 1H), 1.69-1.55 (m, 2H), 1.00 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 197.0, 176.7, 137.4, 136.8, 135.6, 128.6, 128.3, 128.1, 127.7, 124.7, 83.9, 34.3, 31.6, 26.8, 21.2, 14.0. HRMS (ESI) m/z Calcd for $[\text{C}_{16}\text{H}_{16}\text{O}_3, \text{M} + \text{H}]^+$: 257.1172; Found: 257.1175.

Optical Rotation: $[\alpha]_{\text{D}}^{25}$ 169.8 ($c = 1.0, \text{CHCl}_3$). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_{\text{R}} = 12.951$ min for minor isomer, $t_{\text{R}} = 14.161$ min for major isomer).




The reaction of 1-naphthol derivative **12k** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 24 h afforded compound **13k** (32.9 mg) in 61% yield and as a white solid. The title compound **13k** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.4$, petroleum ether/ethyl acetate = 3/1). ^1H NMR (400 MHz, CDCl_3) δ 8.01 (dd, $J = 7.7, 1.5$ Hz, 1H), 7.65 (td, $J = 7.6, 1.5$ Hz, 1H), 7.47-7.34 (m, 2H), 5.98 (s, 1H), 2.85 (ddd, $J = 17.6, 11.4, 9.5$ Hz, 1H), 2.58 (td, $J = 8.8, 8.0, 2.1$ Hz, 1H), 2.52 (ddd, $J = 9.1, 5.3, 2.0$ Hz, 2H), 2.38 (ddd, $J = 13.4, 9.5, 2.1$ Hz, 1H), 2.15 (ddd, $J = 13.4, 11.4, 9.5$ Hz, 1H), 1.63-1.51 (m, 2H), 1.49-1.35 (m, 2H), 0.94 (t, $J = 7.3$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 197.0, 176.7, 137.4, 137.1, 135.6, 128.6, 128.1, 128.1, 127.7, 124.7, 83.9, 32.0, 31.6, 30.2, 26.9, 22.6, 14.0. HRMS (ESI) m/z Calcd for $[\text{C}_{17}\text{H}_{18}\text{O}_3, \text{M} + \text{H}]^+$: 271.1328; Found: 271.1325.


Optical Rotation: $[\alpha]_D^{25}$ 160.6 ($c = 1.0$, CHCl_3). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 11.667$ min for minor isomer, $t_R = 12.305$ min for major isomer).



The reaction of 1-naphthol derivative **12I** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 24 h afforded compound **13I** (46.3 mg) in 95% yield as a white solid. The title compound **13I** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 3/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.98 (d, $J = 8.6$ Hz, 1H), 6.88 (dd, $J = 8.7, 2.5$ Hz, 1H), 6.70 (d, $J = 2.5$ Hz, 1H), 6.59 (d, $J = 9.9$ Hz, 1H), 6.20 (d, $J = 9.9$ Hz, 1H), 3.89 (s, 3H), 2.93 (m, 1H), 2.58 (ddd, $J = 17.6, 9.6, 2.1$ Hz, 1H), 2.39 (ddd, $J = 12.2, 9.6, 2.2$ Hz, 1H), 2.16 (m, 1H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 195.0, 176.9, 165.7, 139.2, 133.4, 130.6, 128.0, 120.7, 114.5, 113.0, 83.1, 55.9, 31.7, 26.9. **HRMS** (ESI) m/z Calcd for $[\text{C}_{14}\text{H}_{12}\text{O}_4, \text{M} + \text{H}]^+$: 245.0808; Found: 245.0809.



Optical Rotation: $[\alpha]_D^{25}$ 138.3 ($c = 1$, CHCl_3). 97% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 75:25, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 12.767$ min for minor isomer, $t_R = 14.716$ min for major isomer).





The reaction of 2-naphthol derivative **12m** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), HFIP (10 mmol, 50 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13m** (31.1 mg) in 73% yield as a white solid. The title compound **13m** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (3/1 to 1/1). (*R*_f = 0.5, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, *J* = 7.7 Hz, 1H), 7.47 (dd, *J* = 9.3, 6.7 Hz, 2H), 7.43-7.33 (m, 2H), 6.17 (d, *J* = 9.9 Hz, 1H), 2.84 (ddd, *J* = 17.1, 11.6, 9.3 Hz, 1H), 2.71-2.60 (m, 2H), 2.15 (ddd, *J* = 14.0, 11.6, 9.7 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 197.7, 176.6, 146.2, 140.7, 131.2, 129.9, 129.3, 129.3, 125.9, 122.7, 86.0, 35.9, 26.7. HRMS (ESI) *m/z* Calcd for [C₁₃H₁₀O₃, M + H]⁺: 215.0698; Found: 215.0703.



Optical Rotation: [α]_D²⁵ 264.2 (*c* = 1.0, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t*_R = 11.667 min for minor isomer, *t*_R = 12.305 min for major isomer).



The reaction of 2-naphthol derivative **12n** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), HFIP (10 mmol, 50 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 24 h afforded compound **13n** (39.0 mg) in 80% yield as a white solid. The title compound **13n** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (3/1 to 1/1). (*R*_f = 0.5, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.40 (d, *J* = 9.9 Hz, 1H), 7.24 (d, *J* = 2.7 Hz, 1H), 7.05 (d, *J* = 2.6 Hz, 1H), 6.85 (dd, *J* = 8.4, 2.6 Hz, 1H), 5.99 (d, *J* = 9.9 Hz, 1H), 3.83 (s, 3H), 2.80 (ddd, *J*

= 17.4, 11.7, 9.4 Hz, 1H), 2.66-2.57 (m, 2H), 2.11 (ddd, $J = 13.8, 11.7, 9.6$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 197.6, 176.7, 162.3, 146.2, 143.1, 131.7, 122.3, 119.9, 114.5, 111.7, 86.1, 55.8, 36.2, 26.7. **HRMS** (ESI) m/z calcd for $[\text{C}_{14}\text{H}_{12}\text{O}_4 + \text{H}]^+$: 245.0814, found: 245.0808.



Optical Rotation: $[\alpha]_D^{25}$ 232.2 ($c = 1.0, \text{CHCl}_3$). 95% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 28.241$ min for minor isomer, $t_R = 32.807$ min for major isomer).



The reaction of 2-naphthol derivative **12o** (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), HFIP (10 mmol, 50 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 24 h afforded compound **13o** (39.0 mg) in 61% yield as a white solid. The title compound **13o**


was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (3/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). ^1H NMR (400 MHz, CDCl_3) δ 7.58 (dd, $J = 8.3, 2.0$ Hz, 1H), 7.49 (d, $J = 2.0$ Hz, 1H), 7.45-7.37 (m, 2H), 6.20 (d, $J = 10.0$ Hz, 1H), 2.82 (ddd, $J = 16.9, 11.6, 9.0$ Hz, 1H), 2.68-2.59 (m, 2H), 2.11 (ddd, $J = 14.3, 11.6, 9.7$ Hz, 1H). ^{13}C NMR (100 MHz, CDCl_3) δ 196.9, 176.2, 144.5, 139.4, 133.8, 132.4, 131.1, 127.6, 123.9, 123.2, 85.5, 35.7, 26.6. **HRMS** (ESI) m/z calcd for $[\text{C}_{13}\text{H}_9\text{BrO}_3 + \text{H}]^+$: 292.9808, 294.9788; Found: 292.9803, 294.9784.


Optical Rotation: $[\alpha]_D^{25}$ 172.5 ($c = 0.5, \text{CHCl}_3$). 93% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 25.737$ min for minor isomer, $t_R = 32.325$ min for major isomer).





The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14a** (30.0 mg) in 76% yield as a white solid. The title compound **14a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.95 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.53 (td, *J* = 7.5, 1.4 Hz, 1H), 7.32 (td, *J* = 7.6, 1.2 Hz, 1H), 7.17 (dd, *J* = 7.6, 1.1 Hz, 1H), 6.49 (d, *J* = 9.9 Hz, 1H), 6.16 (d, *J* = 9.9 Hz, 1H), 4.36-4.26 (m, 1H), 4.19-4.09 (m, 1H), 2.27-2.16 (m, 2H), 2.08-1.99 (m, 1H), 1.96-1.85 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.0, 137.5, 136.7, 134.8, 129.0, 128.1, 127.4, 127.2, 125.7, 84.3, 70.7, 36.6, 25.3. HRMS (ESI) *m/z* Calcd for [C₁₃H₁₂O₂, M + H]⁺: 201.0910; Found: 201.0907.

Optical Rotation: [α]_D²⁵ 247.2 (*c* = 0.5, CHCl₃). 96% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 6.749 min for major isomer, *t_R* = 8.22 min for minor isomer).







The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14b** (22.1 mg) in 52% yield as a solid. The title compound **14b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.59 (td, *J* = 7.6, 1.5 Hz, 1H), 7.34 (td, *J* = 7.7, 6.3 Hz, 2H), 5.97 (s, 1H), 4.30-4.21 (m, 1H), 4.17-4.06 (m, 1H), 2.19 (ddd, *J* = 11.8, 7.7, 3.9 Hz, 2H), 2.12 (s, 3H), 2.07-1.99 (m, 1H), 1.92-1.82 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.1, 138.5, 134.7, 133.2, 130.6, 129.0, 127.9, 127.4, 124.4, 84.1, 70.4, 36.4, 25.4, 19.4. HRMS (ESI) *m/z* Calcd for [C₁₄H₁₄O₂, M + H]⁺: 215.1067; Found: 215.1070. **Optical Rotation:** [α]_D²⁵ 216.2 (*c* = 0.5, CHCl₃). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 6.880 min for major isomer, *t_R* = 8.537 min for minor isomer).



The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14c** (28.7 mg) in 63% yield as oil. The title compound **14c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.97 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.58 (td, *J* = 7.6, 1.5 Hz, 1H), 7.39-7.31 (m, 2H), 5.96 (s,



1H), 4.32-4.25 (m, 1H), 4.17-4.11 (m, 1H), 2.55-2.47 (m, 2H), 2.24-2.16 (m, 2H), 2.07-1.99 (m, 1H), 1.91-1.83 (m, 1H), 1.21 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 202.3, 138.0, 135.9, 134.6, 131.3, 129.3, 127.8, 127.5, 123.9, 84.4, 70.5, 36.5, 25.3, 25.1, 12.6. HRMS (ESI) m/z Calcd for $[\text{C}_{15}\text{H}_{16}\text{O}_2, \text{M} + \text{H}]^+$: 229.1223; Found: 229.1225.

Optical Rotation: $[\alpha]_D^{25}$ 176.6 ($c = 1$, CHCl_3). 91% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 5.463$ min for major isomer, $t_R = 7.002$ min for minor isomer).




The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 16 h afforded compound **14c** (30.1 mg) in 64% yield as oil. The title compound **14c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ^1H NMR (400 MHz, CDCl_3) δ 7.97 (dd, $J = 7.7, 1.5$ Hz, 1H), 7.57 (td, $J = 7.6, 1.5$ Hz, 1H), 7.38-7.28 (m, 2H), 5.95 (s, 1H), 4.31-4.24 (m, 1H), 4.17-4.08 (m, 1H), 2.50-2.41 (m, 2H), 2.24-2.14 (m, 2H), 2.06-1.97 (m, 1H), 1.93-1.83 (m, 1H), 1.66-1.56 (m, 2H), 0.99 (t, $J = 7.4$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 202.3, 137.9, 134.6, 134.3, 132.5, 129.3, 127.7, 127.5, 124.1, 84.4, 70.4, 36.6, 34.5, 25.3, 21.3, 14.1. HRMS (ESI) m/z Calcd for $[\text{C}_{16}\text{H}_{18}\text{O}_2, \text{M} + \text{H}]^+$: 243.1380; Found: 243.1381.


Optical Rotation: $[\alpha]_D^{25}$ 169.8 ($c = 1.0$, CHCl_3). 92% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 4.875$ min for major isomer, $t_R = 5.992$ min for minor isomer).




The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 16 h afforded compound **14e** (31.2 mg) in 61% yield as oil. The title compound **14e** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.97 (dd, $J = 7.7, 1.5$ Hz, 1H), 7.57 (td, $J = 7.6, 1.5$ Hz, 1H), 7.39-7.30 (m, 2H), 5.95 (s, 1H), 4.31-4.25 (m, 1H), 4.17-4.10 (m, 1H), 2.51-2.43 (m, 2H), 2.24-2.15 (m, 2H), 2.06-1.98 (m, 1H), 1.92-1.83 (m, 1H), 1.60-1.52 (m, 2H), 1.46-1.36 (m, 2H), 0.94 (t, $J = 7.3$ Hz, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 202.3, 137.9, 134.6, 134.6, 132.4, 129.4, 127.7, 127.5, 124.1, 84.4, 70.4, 36.6, 32.1, 30.4, 25.3, 22.7, 14.1. **HRMS** (ESI) m/z Calcd for $[\text{C}_{15}\text{H}_{12}\text{O}_4, \text{M} + \text{H}]^+$: 257.0807; Found: 257.0808.

Optical Rotation: $[\alpha]_D^{25}$ 176.4 ($c = 0.5$, CHCl_3). 88% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 4.779$ min for major isomer, $t_R = 6.044$ min for minor isomer).







The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14f** (41.1 mg) in 71% yield as a solid. The title compound **14f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.99-7.87 (m, 1H), 7.43 (td, *J* = 7.6, 1.3 Hz, 1H), 7.28-7.14 (m, 7H), 5.91 (s, 1H), 4.25 (td, *J* = 7.7, 5.3 Hz, 1H), 4.12-4.03 (m, 1H), 3.79 (s, 2H), 2.25-2.10 (m, 2H), 2.04-1.94 (m, 1H), 1.92-1.81 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 202.0, 138.4, 137.6, 135.4, 134.6, 133.1, 129.3, 128.7, 128.7, 127.9, 127.5, 126.6, 124.8, 84.5, 70.6, 38.9, 36.7, 25.2. HRMS (ESI) *m/z* Calcd for [C₂₀H₁₈O₂, M + H]⁺: 291.1380; Found: 291.1382. **Optical Rotation:** [α]_D²⁵ 136.0 (*c* = 1, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 9.717 min for major isomer, *t_R* = 10.845 min for minor isomer).



RT [min]	Type	Width [min]	Area	Height	Area%
10.133	BB	1.31	3202.88	205.56	50.08
11.264	BB	1.15	3192.97	178.05	49.92
Sum			6395.85		





Name	RT [min]	Type	Width [min]	Area	Height	Area%	Name
	9.717	BV	1.20	4937.78	334.51	95.94	
	10.845	VB	0.98	208.98	12.41	4.06	
Sum				5146.76			



The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and ^mCPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14g** (38.6 mg) in 70% yield as oil. The title compound **14g** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.03 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.51-7.33 (m, 7H), 7.09 (d, *J* = 7.8 Hz, 1H), 6.11 (s, 1H), 4.36-4.29 (m, 1H), 4.22-4.10 (m, 1H), 2.37-2.30 (m, 1H), 2.28-2.19 (m, 1H), 2.12-



1.97 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 201.8, 138.7, 137.9, 137.6, 135.2, 134.4, 129.3, 129.0, 128.6, 128.2, 128.0, 127.6, 126.8, 84.5, 70.6, 36.8, 25.5. HRMS (ESI) m/z Calcd for $[\text{C}_{19}\text{H}_{16}\text{O}_2, \text{M} + \text{H}]^+$: 277.1223; Found: 277.1223.

Optical Rotation: $[\alpha]_D^{25}$ 98.0 ($c = 0.5$, CHCl_3). 84% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 5.887$ min for major isomer, $t_R = 7.905$ min for minor isomer).




The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH_2Cl_2 at -20 °C for 16 h afforded compound **14h** (40.1 mg) in 74% yield as oil. The title compound **14h** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 3/1). ^1H NMR (400 MHz, CDCl_3) δ 7.97 (d, $J = 8.3$ Hz, 1H), 7.71-7.61 (m, 2H), 7.48-7.36 (m, 1H), 6.62 (s, 1H), 4.32-4.22 (m, 1H), 4.19-4.08 (m, 1H), 2.31-2.13 (m, 2H), 2.13-1.91 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 199.8, 137.9, 135.7, 135.0, 129.4, 129.0, 128.2, 127.5, 119.8, 85.6, 70.8, 36.5, 25.4. HRMS (ESI) m/z Calcd for $[\text{C}_{13}\text{H}_{11}\text{O}_2\text{Br}, \text{M} + \text{Na}]^+$: 300.9840; Found: 300.9848.


Optical Rotation: $[\alpha]_D^{25}$ 137 ($c = 0.5$, CHCl_3). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 7.437$ min for major isomer, $t_R = 8.982$ min for minor isomer).



The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14i** (34.8 mg) in 74% yield as oil. The title compound **14i** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, *J* = 7.6 Hz, 1H), 7.66-7.55 (m, 2H), 7.37 (td, *J* = 7.3, 1.7 Hz, 1H), 6.28 (s, 1H), 4.20 (m, 1H), 4.12-4.03 (m, 1H), 2.16 (m, 2H), 2.00 (ddd, *J* = 16.0, 8.9, 3.6 Hz, 1H), 1.94-1.82 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 199.7, 135.0, 134.9, 133.4, 129.4, 129.1, 128.9, 127.5, 125.5, 84.7, 70.7, 36.6, 25.4. HRMS (ESI) *m/z* Calcd for [C₁₃H₁₁O₂Cl, *M* + *H*]⁺: 235.0520; Found: 235.0508.


Optical Rotation: [α]_D²⁵ 110.5 (*c* = 0.5, CHCl₃). 95% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 5.164 min for major isomer, *t_R* = 6.914 min for minor isomer)






The reaction of 1-naphthol derivative (0.2 mmol, 1 equiv.), **Cat-8** (0.03 mmol, 15 mol%), EtOH (1 mmol, 5 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) were added to dry CH₂Cl₂ at -20 °C for 16 h afforded compound **14j** (33.6 mg) in 73% yield as a white solid. The title compound **14j** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (10/1 to 3/1). (*R_f* = 0.6, petroleum ether/ethyl acetate = 3/1). ¹H NMR (400 MHz, CDCl₃) δ 8.37 (d, *J* = 8.6 Hz, 1H), 7.25 (dd, *J* = 8.6, 2.5 Hz, 1H), 7.06 (d, *J* = 2.5 Hz, 1H), 6.87 (d, *J* = 9.8 Hz, 1H), 6.60 (d, *J* = 9.8 Hz, 1H), 4.78-4.67 (m, 1H), 4.62-4.51 (m, 1H), 4.29 (s, 3H), 2.73-2.59 (m, 2H), 2.51-2.41 (m, 1H), 2.39-2.25 (m, 1H). ¹³C NMR (100 MHz, CDCl₃) δ 200.4, 164.9, 139.7, 137.7, 129.9, 125.6, 122.4, 113.7, 112.1, 83.6, 70.8, 55.7, 37.0, 25.5. HRMS (ESI) *m/z* Calcd for [C₁₄H₁₄O₃, M + H]⁺: 231.1016; Found: 231.1016.


Optical Rotation: [α]_D²⁵ 172.5 (c = 0.5, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 9.820 min for major isomer, *t_R* = 12.205 min for minor isomer).



7.2 Characterization of oxidative spirocyclization





General procedure: To a Schlenk tube containing **Cat-9** (0.03 mmol, 15 mol%), *m*CPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.), H₂O (2 mmol, 10 equiv.) and MeNO₂ (3 mL) were added **15** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at -10 °C for 72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. Finally, the organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the product **16**.



The reaction of the **15a** (55.4 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16a** (29.7 mg) in 54% yield as a white solid. The title compound **16a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). (*R*_f = 0.5, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 7.98 (d, *J* = 7.8 Hz, 1H), 7.68-7.59 (m, 2H), 7.44-7.28 (m, 7H), 7.02-6.96 (m, 2H), 6.96-6.89 (m, 7H), 6.03 (d, *J* = 9.6 Hz, 2H), 3.28 (s, 7H); ¹³C NMR (100 MHz, CDCl₃) δ 194.2, 172.9, 145.0, 138.4, 135.5, 129.5, 129.3, 128.8, 128.7, 128.5, 128.2, 128.2, 127.8, 123.5, 123.2, 109.1, 64.5, 27.0., HRMS (ESI) *m/z* Calcd for [C₁₈H₁₃NO₂, M + H]⁺:276.1019; Found: 276.1017.



Optical Rotation: $[\alpha]_D^{25}$ -4.2 ($c = 1.0$, CHCl_3). 95% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 7.418$ min for minor isomer, $t_R = 11.691$ min for major isomer).



The reaction of the **15b** (58.2 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H_2O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO_2 (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16b** (34.68 mg) in

60% yield as a white solid. The title compound **16b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.00 (d, $J = 7.7$ Hz, 1H), 7.68-7.60 (m, 1H), 7.44-7.33 (m, 2H), 7.16-7.09 (m, 1H), 6.91 (d, $J = 9.6$ Hz, 1H), 6.81 (d, $J = 8.0$ Hz, 1H), 6.75 (s, 1H), 6.02 (d, $J = 9.6$ Hz, 1H), 3.26 (s, 3H), 2.24 (s, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 194.4, 172.8, 142.6, 138.5, 135.4, 132.9, 129.8, 129.5, 128.8, 128.8, 128.5, 128.2, 128.0, 127.8, 124.3, 108.9, 64.6, 27.1, 21.1., **HRMS** (ESI) m/z Calcd for $[\text{C}_{19}\text{H}_{15}\text{NO}_2, \text{M}+\text{H}]^+$: 290.1176, found 290.1175.


Optical Rotation: $[\alpha]_D^{25}$ 54.9 ($c = 1.0$, CHCl_3). 94% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 6.351$ min for minor isomer, $t_R = 9.763$ min for major isomer).




The reaction of the **15c** (66.6 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16c** (42.3 mg) in 64%

yield as a white solid. The title compound **16c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). (*R*_f = 0.5, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 7.7 Hz, 1H), 7.69-7.61 (m, 1H), 7.41-7.33 (m, 3H), 6.97-6.89 (m, 2H), 6.85 (d, *J* = 8.3 Hz, 1H), 6.03 (d, *J* = 9.6 Hz, 1H), 3.26 (s, 3H), 1.22 (s, 9H).; ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 172.8, 146.6, 142.6, 138.5, 135.5, 129.7, 128.8, 128.8, 128.6, 128.2, 128.2, 127.9, 126.2, 120.7, 108.6, 64.9, 34.7, 31.6, 27.1., **HRMS** (ESI) *m/z* Calcd for [C₂₂H₂₁NO₂, M+H]⁺: 332.1646, found 332.1648.

Optical Rotation: [α]_D²⁵ 88.6 (*c* = 0.5, CHCl₃). 94% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t*_R = 4.505 min for minor isomer, *t*_R = 8.360 min for major isomer).







The reaction of the **15d** (61.4 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dried, 3.0 mL) at -10 °C for 72 h afforded compound **16d** (45.14 mg) in

74% yield as a white solid. The title compound **16d** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 2/1). ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.66-7.62 (m, 1H), 7.44-7.32 (m, 2H), 6.91 (d, *J* = 9.6 Hz, 1H), 6.88-6.77 (m, 2H), 6.56 (d, *J* = 2.3 Hz, 1H), 6.02 (d, *J* = 9.6 Hz, 1H), 3.69 (s, 3H), 3.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.2, 172.5, 156.3, 138.4, 138.4, 135.5, 130.0, 129.4, 128.9, 128.5, 128.2, 128.2, 127.9, 113.7, 111.0, 109.4, 64.9, 55.9, 27.2., HRMS (ESI) *m/z* Calcd for [C₁₉H₁₅NO₃, M+H]⁺ :306.1125, found 306.1125.

Optical Rotation: [α]_D²⁵ 57 (c = 1, CHCl₃). 92% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 8.380 min for minor isomer, *t_R* = 15.117 min for major isomer).





The reaction of the **15e** (58.2 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H₂O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO₂ (dry, 3.0 ml) at

-10 °C for 72 h afforded compound **16e** (31.2 mg) in 54% yield as oil. The title compound **16e** was isolated through chromatography on silica gel eluting with

petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.98 (d, $J = 9.2$ Hz, 1H), 7.68-7.60 (m, 1H), 7.42-7.29 (m, 3H), 7.02-6.87 (m, 4H), 6.04 (d, $J = 9.6$ Hz, 1H), 3.91-3.74 (m, 2H), 1.33 (t, $J = 7.2$ Hz, 3H).; **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 194.2, 172.6, 144.1, 138.4, 135.4, 129.5, 129.4, 129.0, 128.8, 128.8, 128.5, 128.2, 127.8, 123.7, 123.0, 109.3, 64.5, 35.6, 12.7., **HRMS** (ESI) m/z Calcd for $[\text{C}_{19}\text{H}_{15}\text{NO}_2, \text{M}+\text{H}]^+$: 290.1176, found 290.1178.


Optical Rotation: $[\alpha]_D^{25} -14.7$ ($c = 0.5$, CHCl_3). 95% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 7.225$ min for minor isomer, $t_R = 10.946$ min for major isomer).




The reaction of the **15f** (67.4 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (52.9 mg, 0.26 mmol, 1.3 equiv.), **Cat-9** (42.0 mg, 0.03 mmol, 15 mol%), H_2O (36.0 mg, 2.0 mmol, 10.0 equiv.), TFE (1.0g, 10 mmol, 50.0 equiv.) in MeNO_2 (dry., 3.0 mL) at -10 °C for 24 h afforded compound **16f** (27.1 mg) in 40% yield as oil. The title compound **16f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 2/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 2/1). **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 8.00 (d, $J = 7.7$ Hz, 1H), 7.68-7.60 (m, 1H), 7.57-7.46 (m, 4H), 7.45-7.34 (m, 3H), 7.28-7.20 (m, 1H), 7.03-6.93 (m, 3H), 6.87 (d, $J = 8.0$ Hz, 1H), 6.19 (d, $J = 9.6$ Hz, 1H).; **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 194.1, 172.4, 145.1, 138.4, 135.5, 134.3, 129.8, 129.4, 129.3, 128.9, 128.9, 128.5, 128.4,

128.4, 128.2, 127.9, 126.8, 123.8, 123.6, 110.4, 64.6., **HRMS** (ESI) m/z Calcd for $[C_{23}H_{15}NO_2, M+Na]^+$: 338.1176, found 338.1178.


Optical Rotation: $[\alpha]_D^{25}$ -128.2 (c = 1, $CHCl_3$). 96% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.775 min for minor isomer, t_R = 24.603 min for major isomer).



7.3 Characterization of direct C(sp²)-H/C(sp³)-H cross-coupling





General procedure: To a Schlenk tube containing **Cat-3** (0.03 mmol, 15 mol%), *m*CPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) and H₂O (0.6 mmol, 3 equiv.) and MeCN (3 mL) were added **17** (0.2 mmol, 1.0 equiv.), the reaction mixture was stirred at 25 °C for 16 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the product **18**.



The reaction of the **17a** (56.4 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18a** (40.0 mg) in 72% yield as a white solid. The title compound **18a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 1/1). **¹H NMR** (400 MHz, CDCl₃) δ7.36 (t, *J* = 8.4 Hz, 1H), 7.02 (t, *J* = 7.6 Hz, 1H), 6.96 (d, *J* = 7.8 Hz, 1H), 6.88 (d, *J* = 6.2 Hz, 1H), 3.31 (s, 2H).; **¹³C NMR** (100 MHz, CDCl₃) δ172.3, 145.4, 129.7, 127.9, 124.0, 123.4, 109.0, 62.4, 27.2. **HRMS** (ESI) *m/z* Calcd for [C₁₇H₁₄N₂O₂, M+H]⁺: 279.1128, found 279.1129.



Optical Rotation: $[\alpha]_D^{25} -71$ ($c = 0.5$, CHCl_3). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 11.836$ min for major isomer, $t_R = 27.463$ min for minor isomer).



The reaction of the **17b** (62.0 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H_2O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded


compound **18b** (48.9 mg) in 80% yield as a white solid. The title compound **18b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.15 (dd, $J = 8.0, 1.7$ Hz, 1H), 6.85 (d, $J = 8.0$ Hz, 1H), 6.71 (s, 1H), 3.29 (s, 3H), 2.25 (s, 3H).; $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.4, 143.0, 133.1, 129.9, 128.0, 124.7, 108.6, 62.5, 27.1, 21.1., **HRMS** (ESI) m/z Calcd for $[\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2, \text{M}+\text{H}]^+$: 307.1441, found 307.1441.


Optical Rotation: $[\alpha]_D^{25} -111.2$ ($c = 0.5$, CHCl_3). 82% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 7.751$ min for minor isomer, $t_R = 9.406$ min for major isomer).



The reaction of the **17c** (71.6 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18c** (33.3 mg) in 47% yield as a white solid. The title compound **18c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.57-7.21 (m, 7H), 7.15-6.89 (m, 5H), 6.84 (d, *J* = 7.9 Hz, 1H), 5.06 (t, *J* = 11.1 Hz, 2H), 3.36 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 172.3, 145.5, 144.4, 135.3, 129.8, 129.6, 129.0, 127.9, 127.9, 127.8, 127.2, 124.0, 123.9, 123.5, 123.4, 110.0, 109.0, 62.4, 44.3, 27.1., HRMS (ESI) *m/z* Calcd for [C₂₃H₁₈N₂O₂, M+H]⁺: 355.1441, found 355.1440.

Optical Rotation: [α]_D²⁵ -29.2 (*c* = 0.5, CHCl₃). 89% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 22.980 min for major isomer, *t_R* = 26.662 min for minor isomer).







The reaction of the **17d** (78.4 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18d** (31.8

mg) in 41% yield as a white solid. The title compound **18d** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). (*R_f* = 0.5, petroleum ether/ethyl acetate = 1/1). ¹H NMR (400 MHz, CDCl₃) δ 7.43-7.33 (m, 5H), 7.32-7.27 (m, 1H), 7.25-7.22 (m, 1H), 7.00 (td, *J* = 7.6, 1.0 Hz, 1H), 6.96-6.84 (m, 3H), 6.81 (d, *J* = 7.9 Hz, 1H), 5.11-4.89 (m, 2H), 3.32 (s, 3H).; ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 171.8, 144.4, 144.1, 135.1, 129.9, 129.8, 129.3, 129.1, 128.8, 127.9, 127.2, 127.2, 124.5, 124.1, 123.6, 110.2, 109.9, 62.3, 44.5, 27.3., HRMS (ESI) *m/z* Calcd for [C₂₃H₁₇ClN₂O₂, M+H]⁺: 389.1051, 391.1022, found 389.1057, 391.1039



Optical Rotation: [α]_D²⁵ -74.8 (*c* = 0.5, CHCl₃). 86% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 15.267 min for major isomer, *t_R* = 21.668 min for minor isomer).



The reaction of the **17e** (83.2 mg, 0.2 mmol, 1.0 equiv.), *m*CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H₂O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded

compound **18e** (51.0 mg) in 62% yield as a white solid. The title compound **18e** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.14 (dt, $J = 8.3, 1.4$ Hz, 1H), 7.61 (d, $J = 1.6$ Hz, 1H), 7.40-7.34 (m, 4H), 7.30 (p, $J = 2.9$ Hz, 1H), 7.24 (dd, $J = 7.8, 1.4$ Hz, 1H), 7.05-6.97 (m, 2H), 6.84 (dd, $J = 23.5, 7.7$ Hz, 2H), 5.13-4.89 (m, 2H), 3.85 (s, 3H), 3.37 (s, 3H).; $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 172.5, 172.0, 166.5, 149.5, 144.5, 135.1, 132.4, 129.9, 129.1, 127.9, 127.2, 127.2, 125.5, 125.4, 124.1, 123.7, 110.2, 108.6, 62.1, 52.3, 44.5, 27.4. **HRMS** (ESI) m/z Calcd for $[\text{C}_{25}\text{H}_{20}\text{N}_2\text{O}_4, \text{M}+\text{H}]^+$: 413.1496, found 413.1496.


Optical Rotation: $[\alpha]_D^{25} -176.6$ ($c = 0.5$, CHCl_3). 87% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 15.267$ min for major isomer, $t_R = 21.668$ min for minor isomer).




The reaction of the **17f** (74.4 mg, 0.2 mmol, 1.0 equiv.), m CPBA (105.6 mg, 0.52 mmol, 2.6 equiv.), **Cat-3** (38.0 mg, 0.03 mmol, 15 mol%), H_2O (10.8 mg, 0.6 mmol, 3.0 equiv.), TFE (60.0g, 0.6 mmol, 3.0 equiv.) in MeCN (dry, 3.0 mL) at room temperature for 16 h afforded compound **18f** (38.3 mg) in 52% yield as a white solid. The title compound **18f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (5/1 to 1/1). ($R_f = 0.5$, petroleum ether/ethyl acetate = 1/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.57-7.33 (m, 5H), 7.29 (d, $J = 6.9$ Hz, 1H), 7.22 (t, $J = 7.7$ Hz, 1H), 7.01 (dq, $J = 14.2, 7.5$ Hz, 3H), 6.90 (dd, $J = 17.3, 7.4$ Hz, 2H), 6.80 (d, $J = 7.9$ Hz, 1H), 5.11-4.88 (m, 2H),

4.02-3.75 (m, 2H), 1.37 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 171.9, 144.6, 144.4, 135.3, 129.7, 129.5, 129.0, 128.2, 128.1, 127.8, 127.2, 124.1, 123.8, 123.4, 123.3, 110.0, 109.1, 62.4, 44.3, 35.6, 12.8., **HRMS** (ESI) m/z Calcd for $[\text{C}_{24}\text{H}_{20}\text{N}_2\text{O}_2, \text{M}+\text{H}]^+$: 368.1598, found 369.1604.


Optical Rotation: $[\alpha]_D^{25} -11.6$ ($c = 0.5$, CHCl_3). 89% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 12.404$ min for major isomer, $t_R = 37.330$ min for minor isomer).



7.4 Characterization of oxidative fluorination of keto esters.





General procedure: To a Teflon tube containing β -ketoesters **19** (0.20 mmol, 1.0 equiv.), **Cat-38** (0.03 mmol, 15 mol%), and CHCl_3 (8 mL) were added $\text{NEt}_3\cdot 3\text{HF}$ (2 mmol, 10 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) in turn, the reaction mixture was stirred at 25 °C for 24-72 hours, which was then quenched in the sequence of saturated $\text{Na}_2\text{S}_2\text{O}_3$ and NaHCO_3 aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na_2SO_4 . Finally, the mixture was concentrated *in vacuo*, and then the residue was purified by silica gel column chromatography to afford the desired product **20**.





The reaction of the β -keto ester **19a** (44.8 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3\cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20a** (27.6 mg) in 57% yield as a white solid. The title compound **20a** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). (R_f = 0.6, petroleum ether/ethyl acetate = 5/1). **^1H NMR** (400 MHz, CDCl_3) δ 7.80 (d, J = 2.1 Hz, 1H), 7.66 (dd, J = 8.2, 2.1 Hz, 1H), 7.46 (d, J = 8.2 Hz, 1H), 3.81 (s, 3H), 3.77 (dd, J = 17.7, 10.8 Hz, 1H), 3.41 (dd, J = 22.9, 17.7 Hz, 1H).; **^{13}C NMR** (100 MHz, CDCl_3) δ 194.1 (d, $^2J_{\text{C-F}}$ = 18.3 Hz), 167.4 (d, $^2J_{\text{C-F}}$ = 27.7 Hz), 149.0 (d, $^3J_{\text{C-F}}$ = 3.7 Hz), 136.9, 135.3, 134.8(d, $^3J_{\text{C-F}}$ = 1.4 Hz), 128.0, 125.5, 94.9 (d, $^1J_{\text{C-F}}$ = 202.8 Hz), 53.6, 38.0 (d, $^2J_{\text{C-F}}$ = 24.0 Hz)., **^{19}F NMR** (376 MHz, CDCl_3) δ -164.16. **GC-MS (EI)** m/z Calcd for $[\text{C}_{11}\text{H}_8\text{ClFO}]^+$: 242.0, 244.0; found 242.0, 244.0

Optical Rotation: $[\alpha]_D^{25}$ 4.2 ($c = 0.5$, CHCl_3). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 15.678$ min for major isomer, $t_R = 16.611$ min for minor isomer).




The reaction of the β -keto ester **19b** (47.6mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20b** (26.6 mg) in 52% yield as oil. The title compound **20b** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.79 (d, $J = 2.4$ Hz, 1H), 7.66 (dd, $J = 8.1, 2.4$ Hz, 1H), 7.46 (d, $J = 8.3$ Hz, 1H), 4.27 (q, $J = 7.1$ Hz, 2H), 3.75 (dd, $J = 17.8, 11.0$ Hz, 1H), 3.39 (dd, $J = 23.0, 17.7$ Hz, 1H), 1.25 (t, $J = 7.1$ Hz, 3H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 194.3 (d, $^2J_{\text{C-F}} = 18.2$ Hz), 167.0 (d, $^2J_{\text{C-F}} = 27.6$ Hz), 149.1 (d, $^3J_{\text{C-F}} = 4.4$ Hz), 136.8, 135.2, 134.8, 127.9, 125.4, 94.8 (d, $^1J_{\text{C-F}} = 202.7$ Hz), 62.9, 38.0 (d, $^2J_{\text{C-F}} = 24.0$ Hz), 14.1. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -164.04. **GC-MS (EI)** m/z Calcd for $[\text{C}_{12}\text{H}_{10}\text{ClFO}_3]^+$: 256.0, found 256.0.


Optical Rotation: $[\alpha]_D^{25}$ 2.7 ($c = 1.0$, CHCl_3). 88% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 0.5 mL/min, 30 °C, wavelength = 254 nm, $t_R = 11.849$ min for major isomer, $t_R = 13.353$ min for minor isomer).



The reaction of the β -keto ester **19c** (60.0 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20c** (31.8 mg) in 50% yield as oil. The title compound **20c** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.79 (d, $J = 2.1$ Hz, 1H), 7.65 (dd, $J = 8.2, 2.1$ Hz, 1H), 7.44 (d, $J = 8.1$ Hz, 1H), 7.37-7.30 (m, 3H), 7.30-7.24 (m, 2H), 5.30-5.19 (m, 2H), 3.73 (dd, $J = 17.7, 11.1$ Hz, 1H), 3.39 (dd, $J = 22.8, 17.7$ Hz, 1H).; $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 194.1(d, $^2J_{\text{C-F}} = 18.7$ Hz), 166.9 (d, $^2J_{\text{C-F}} = 28.3$ Hz), 149.0 (d, $^3J_{\text{C-F}} = 3.7$ Hz), 136.9, 135.3, 134.8, 134.6, 128.8, 128.3, 127.9, 125.4, 94.8 (d, $^1J_{\text{C-F}} = 203.0$ Hz), 68.2, 37.9 (d, $^2J_{\text{C-F}} = 24.2$ Hz). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -164.02. **HRMS** (ESI) m/z Calcd for $[\text{C}_{17}\text{H}_{12}\text{ClFO}_3, \text{M}+\text{Na}]^+$:341.0369, found 341.0353.



Optical Rotation: $[\alpha]_D^{25} -1.6$ ($c = 0.25$, CHCl_3). 85% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 8.390$ min for major isomer, $t_R = 9.912$ min for minor isomer).





The reaction of the β -keto ester **19d** (68.8 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20d** (29.7 mg) in 41% yield as white solid. The title compound **20d** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). (R_f = 0.6, petroleum ether/ethyl acetate = 5/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.76 (s, 1H), 7.65-7.60 (m, 1H), 7.44 (d, J = 8.1 Hz, 1H), 3.69 (dd, J = 17.6, 10.0 Hz, 1H), 3.35 (dd, J = 22.5, 17.6 Hz, 1H), 2.13 (s, 3H), 2.02 (d, J = 3.5 Hz, 6H), 1.60 (t, J = 3.4 Hz, 6H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 194.8 (d, $^2J_{\text{C-F}}$ = 18.9 Hz), 165.4 (d, $^2J_{\text{C-F}}$ = 27.6 Hz), 149.2 ($^3J_{\text{C-F}}$, J = 3.6 Hz), 136.5, 135.1, 134.9, 127.8, 125.1, 94.5 (d, $^1J_{\text{C-F}}$ = 202.7 Hz), 84.6, 41.1, 38.1 (d, $^2J_{\text{C-F}}$ = 24.0 Hz), 35.9, 30.9. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -163.60. **HRMS** (ESI) m/z Calcd for $[\text{C}_{20}\text{H}_{20}\text{ClFO}_3, \text{M}+\text{Na}]^+$: 385.0977, found 385.0973.



Optical Rotation: $[\alpha]_D^{25}$ 10.8 (c = 0.5, CHCl_3). 90% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.437 min for major isomer, t_R = 8.714 min for minor isomer).



The reaction of the β -keto ester **19e** (38 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 48 h afforded compound **20e** (20.8 mg) in 50% yield as oil. The title compound **20e** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1).

($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.79 (d, $J = 7.8$ Hz, 1H), 7.68 (m, 1H), 7.49 (m, 1H), 7.46-7.39 (m, 1H), 3.84-3.72 (m, 1H), 3.76 (s, 3H), 3.41 (dd, $J = 23.5, 17.7$ Hz, 1H); **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 195.3 (d, $^2J_{\text{C-F}} = 18.2$ Hz), 167.7 (d, $^2J_{\text{C-F}} = 28.3$ Hz), 150.9 (d, $^3J_{\text{C-F}} = 3.6$ Hz), 136.9, 133.1, 128.7, 126.7 (d, $^3J_{\text{C-F}} = 1.04$ Hz), 125.6, 94.6 (d, $^1J_{\text{C-F}} = 201.3$ Hz), 53.3, 38.2 (d, $^2J_{\text{C-F}} = 24.0$ Hz). **$^{19}\text{F NMR}$** (376 MHz, CDCl_3) δ -164.53. **HRMS** (ESI) m/z Calcd for $[\text{C}_{11}\text{H}_9\text{FO}_3, \text{M}+\text{Na}]^+$: 231.0428, found 231.0422.



Optical Rotation: $[\alpha]_D^{25} -17.0$ ($c = 1.0$, CHCl_3). 80% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 8.124$ min for major isomer, $t_R = 9.052$ min for minor isomer).



The reaction of the β -keto ester **19f** (72.4mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20f** (25.8 mg) in 58% yield as oil. The title compound **20f** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). **$^1\text{H NMR}$** (400 MHz, CDCl_3) δ 7.84 (d, $J = 7.7$ Hz, 1H), 7.71 (td, $J = 7.5, 1.2$ Hz, 1H), 7.54-7.43 (m, 2H), 4.28 (q, $J = 7.1$ Hz, 2H), 3.79 (dd, $J = 17.6, 11.5$ Hz, 1H), 3.44 (dd, $J = 23.3, 17.6$ Hz, 1H), 1.26 (t, $J = 7.1$ Hz, 3H).; **$^{13}\text{C NMR}$** (100 MHz, CDCl_3) δ 195.5 (d, $^2J_{\text{C-F}} = 18.8$ Hz), 167.5 (d, $^2J_{\text{C-F}} = 27.6$ Hz), 151.1 (d, $^3J_{\text{C-F}} = 3.6$ Hz), 136.9, 133.4, 128.8, 126.7, 125.8, 94.6 (d, $^1J_{\text{C-F}} = 201.3$



Hz), 62.8, 38.4 (d, $^2J_{C-F} = 24.0$ Hz), 14.2. ^{19}F NMR (376 MHz, CDCl_3) δ -164.44. HRMS (ESI) m/z Calcd for $[\text{C}_{12}\text{H}_{11}\text{FO}_3, \text{M}+\text{Na}]^+$: 245.0584, found 245.0578.

Optical Rotation: $[\alpha]_D^{25} -3.5$ ($c = 0.5$, CHCl_3). 84% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 8.124$ min for major isomer, $t_R = 9.052$ min for minor isomer).




The reaction of the β -keto ester **19g** (40.8 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20g** (23.9 mg) in 53% yield as a white solid. The title compound **20g** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ^1H NMR (400 MHz, CDCl_3) δ 7.53-7.38 (m, 3H), 3.81 (s, 3H), 3.76 (dd, $J = 17.3, 10.6$ Hz, 1H), 3.40 (dd, $J = 23.0, 18.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.5 (dd, $^2J_{C-F} = 18.8, 3.5$ Hz), 167.5 (d, $^2J_{C-F} = 27.7$ Hz), 162.9 (d, $^1J_{C-F} = 250.6$ Hz), 146.5 (dd, $^3J_{C-F} = 3.5, 2.3$ Hz), 135.0 (d, $^3J_{C-F} = 7.9$ Hz), 128.3 (d, $^3J_{C-F} = 8.0$ Hz), 124.8 (d, $^2J_{C-F} = 23.6$ Hz), 111.5 (d, $^2J_{C-F} = 22.5$ Hz), 95.1 (d, $^1J_{C-F} = 202.4$ Hz), 53.5, 37.8 (d, $^2J_{C-F} = 24.0$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -163.95, δ -111.89. HRMS (ESI) m/z Calcd for $[\text{C}_{11}\text{H}_8\text{FO}_3, \text{M}+\text{H}]^+$: 227.0514, found 227.0508.


Optical Rotation: $[\alpha]_D^{25} 3.2$ ($c = 0.5$, CHCl_3). 83% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 7.943$ min for major isomer, $t_R = 8.470$ min for minor isomer).



The reaction of the β -keto ester **19h** (53.6 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 24 h afforded compound **20h** (36.4 mg) in 64% yield as a white solid. The title compound **20h** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.94 (d, $J = 2.0$ Hz, 1H), 7.80 (dd, $J = 8.2, 2.0$ Hz, 1H), 7.40 (d, $J = 8.2$ Hz, 1H), 3.80 (s, 3H), 3.74 (dd, $J = 17.8, 10.7$ Hz, 1H), 3.37 (dd, $J = 22.9, 17.8$ Hz, 1H).; $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 194.0 (d, $^2J_{\text{C-F}} = 18.3$ Hz), 167.4 (d, $^2J_{\text{C-F}} = 27.7$ Hz), 149.4 (d, $^3J_{\text{C-F}} = 3.7$ Hz), 139.7, 135.0, 128.5, 128.3, 122.9, 94.7 (d, $^1J_{\text{C-F}} = 202.8$ Hz), 53.5, 38.0 (d, $^2J_{\text{C-F}} = 24.2$ Hz). $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -164.2. **GC-MS** (EI) m/z Calcd for $[\text{C}_{11}\text{H}_8\text{BrFO}_3]^+$: 286.0, 288.0; found 286.0, 288.0.



Optical Rotation: $[\alpha]_D^{25}$ 4.8 ($c = 0.5$, CHCl_3). 85% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 8.506$ min for major isomer, $t_R = 9.517$ min for minor isomer).





The reaction of the β -keto ester **19i** (40.8 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 48 h afforded compound **20i** (21.3 mg) in 48% yield as white solid. The title compound **20i** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.67 (d, $J = 7.9$ Hz, 1H), 7.28-7.21 (m, 2H), 3.75 (s, 3H), 3.70 (dd, $J = 17.8, 11.2$ Hz, 1H), 3.33 (dd, $J = 23.4, 17.7$ Hz, 1H), 2.43 (s, 3H).; $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 194.6 (d, $^2J_{\text{C-F}} = 18.2$ Hz), 167.9 (d, $^2J_{\text{C-F}} = 27.9$ Hz), 151.4 (d, $^3J_{\text{C-F}} = 3.8$ Hz), 148.8, 130.9, 130.1, 127.0, 125.5, 95.0 (d, $^1J_{\text{C-F}} = 201.2$ Hz), 53.3, 38.1 (d, $^2J_{\text{C-F}} = 23.9$ Hz), 22.4. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -164.30. **HRMS** (ESI) m/z Calcd for $[\text{C}_{12}\text{H}_{11}\text{FO}_3, \text{M}+\text{Na}]^+$:245.0584, found 245.0576.



Optical Rotation: $[\alpha]_D^{25} -3.5$ ($c = 0.5$, CHCl_3). 85% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 9.458$ min for major isomer, $t_R = 10.943$ min for minor isomer).



The reaction of the β -keto ester **19j** (44.0 mg, 0.20 mmol, 1.0 equiv.), *m*CPBA (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 72 h afforded compound **20j** (21.3 mg) in 50% yield as a white solid. The title compound **20j** was isolated through chromatography on silica gel eluting with petroleum

ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ^1H NMR (400 MHz, CDCl_3) δ 7.77 (d, $J = 8.6$ Hz, 1H), 6.98 (dd, $J = 8.6, 2.2$ Hz, 1H), 6.91 (d, $J = 2.2$ Hz, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 3.75 (dd, $J = 17.7, 11.0$ Hz, 1H), 3.38 (dd, $J = 23.0, 17.7$ Hz, 1H).; ^{13}C NMR (100 MHz, CDCl_3) δ 193.1 (d, $^2J_{\text{C-F}} = 18.2$ Hz), 168.1 (d, $^2J_{\text{C-F}} = 28.3$ Hz), 167.0, 154.2 (d, $^3J_{\text{C-F}} = 3.7$ Hz), 127.7, 126.4, 116.9, 109.9, 95.2 (d, $^1J_{\text{C-F}} = 201.3$ Hz), 56.1, 53.4, 38.4 (d, $^2J_{\text{C-F}} = 24.0$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -163.60. HRMS (ESI) m/z Calcd for $[\text{C}_{12}\text{H}_{11}\text{FO}_4, \text{M}+\text{Na}]^+$:261.0534, found 261.0528


Optical Rotation: $[\alpha]_D^{25}$ 37 ($c = 1$, CHCl_3). 83% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 20.311$ min for minor isomer, $t_R = 23.065$ min for major isomer).



The reaction of the β -keto ester **19k** (44.8 mg, 0.20 mmol, 1.0 equiv.), $^m\text{CPBA}$ (61.8mg, 0.3 mmol, 1.5 equiv.), **Cat-38** (0.03 mmol, 15 mol%), $\text{NEt}_3 \cdot 3\text{HF}$ (334 μL , 2 mmol, 10 equiv.) in CHCl_3 (8 mL) at 25 °C for 48 h afforded compound **20k** (22.3 mg) in 46% yield as a white solid. The title compound **20k** was isolated through chromatography on silica gel eluting with petroleum ether/ethyl acetate (20/1 to 5/1). ($R_f = 0.6$, petroleum ether/ethyl acetate = 5/1). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, $J = 8.2$ Hz, 1H), 7.49 (s, 1H), 7.43 (d, $J = 10.0$ Hz, 1H), 3.79 (s, 3H), 3.77 (dd, $J = 17.9, 11.1$ Hz, 1H), 3.40 (dd, $J = 23.0, 17.8$ Hz, 1H).; ^{13}C NMR (100 MHz, CDCl_3) δ 193.8 (d, $^2J_{\text{C-F}} = 18.2$ Hz), 167.4 (d, $^2J_{\text{C-F}} = 28.2$ Hz), 152.3 (d, $^3J_{\text{C-F}} = 4.2$ Hz), 143.6, 131.7, 129.7, 127.0, 126.8, 94.6 (d, $^1J_{\text{C-F}} = 202.4$ Hz), 53.5,


38.0 ($^2J_{C-F}$, $J = 24.1$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -164.07. GC-MS (EI) m/z
 Calcd for $[\text{C}_{11}\text{H}_8\text{ClFO}]^+$: 242.0, 244.0; found 242.0, 244.0

Optical Rotation: $[\alpha]_D^{25}$ 33 ($c = 1$, CHCl_3). 80% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 90:10, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 10.818$ min for major isomer, $t_R = 13.117$ min for minor isomer).



8. Investigation of the significance for H-bond interactions and tunable chiral pocket


Supplementary Table 5. Investigation of the significance for H-bond interactions and tunable chiral pocket.




General procedure for the control experiment of oxidative dearomatization: To a Schlenk tube containing **Cat** (0.03 mmol, 15 mol%), *m*CPBA (0.3 mmol, 1.5 equiv.) and EtOH (1 mmol, 5 equiv.) were added CH₂Cl₂ (10 mL) and **12a** (0.2 mmol). The reaction mixture was stirred at -20 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated in vacuo and then the residue was purified by silica gel column chromatography to afford the product **13a**.

Experiment of oxidative dearomatization using **Cat-41**: 15% ee (HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C,

wavelength = 254 nm, t_R = 39.989 min for major isomer, t_R = 44.491 min for minor isomer)




Experiment of oxidative dearomatization using **Cat-12**: 97% *ee* (HPLC conditions: Chiralpak AS-H column, *n*-Hexane/*i*-PrOH = 85:15, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 40.588 min for major isomer, t_R = 44.669 min for minor isomer)




General procedure for the control experiment of oxidative spirolactonization. To a Schlenk tube containing **Cat** (0.03 mmol, 15 mol%), *m*CPBA (0.26 mmol, 1.3 equiv.), TFE (10 mmol, 50 equiv.), H₂O (2 mmol, 10 equiv.) and MeNO₂ (3 mL) were added **15a** (0.2 mmol). The reaction mixture was stirred at -10 °C for 72 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. Finally, the organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. The mixture was concentrated *in vacuo* and then the residue was purified by silica gel column chromatography to afford the product **16a**.


Experiment of oxidative spirocyclization using **Cat-43**: 55% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.651 min for minor isomer, t_R = 11.785 min for major isomer).



Experiment of oxidative spirocyclization using **Cat-13**: 93% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.675 min for minor isomer, t_R = 11.887 min for major isomer).




Experiment of oxidative spirocyclization using **Cat-44**: 81% *ee* (HPLC conditions: Chiralpak AD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 7.174 min for minor isomer, t_R = 10.864 min for major isomer).




General procedure for the control experiment of direct C(sp²)-H/C(sp³)-H cross-coupling. To a Schlenk tube containing **Cat** (0.03 mmol, 15 mol%), *m*CPBA (0.52 mmol, 2.6 equiv.), TFA (0.6 mmol, 3 equiv.) and H₂O (0.6 mmol, 3 equiv.) and MeCN (3 mL) were added **17a** (0.2 mmol). The reaction mixture was stirred at 25 °C for 16 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with ethyl acetate, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo* and then the residue was purified by silica gel column chromatography to afford the product **18a**.


Experiment of direct C(sp²)-H/C(sp³)-H cross-coupling using **Cat-45**: 33% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 11.907 min for major isomer, t_R = 27.393 min for minor isomer).



Experiment of direct C(sp²)-H/C(sp³)-H cross-coupling using **Cat-5**: 89% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, t_R = 11.770 min for major isomer, t_R = 27.268 min for minor isomer).




Experiment of direct C(sp²)-H/C(sp³)-H cross-coupling using **Cat-46**: 72% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 70:30, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 12.011 min for major isomer, *t_R* = 28.677min for minor isomer).




General procedure for the control experiment of fluorinated keto esters. To 25 mL Teflon tube containing β -ketoesters **19a** (0.20 mmol), **Cat** (0.03 mmol, 15 mol%), and CHCl₃ (8 mL) were added. Subsequently, NEt₃·3HF (2 mmol, 10 equiv.) and *m*CPBA (0.3 mmol, 1.5 equiv.) was loaded in turn. The reaction mixture was stirred at 25 °C for 24 hours, which was then quenched in the sequence of saturated Na₂S₂O₃ and NaHCO₃ aqueous solution. The organic layer was subsequently extracted with dichloromethane, washed with brine, dried over anhydrous Na₂SO₄. Finally, the mixture was concentrated *in vacuo* and then the residue was purified by silica gel column chromatography to afford desired products **20a**.


Experiment of fluorinated keto esters using **Cat-48**: 80% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, *t_R* = 15.742 min for major isomer, *t_R* = 16.792 min for minor isomer).



Experiment of fluorinated keto esters using **Cat-49**: 52% *ee* (HPLC conditions: Chiralpak OD-H column, *n*-Hexane/*i*-PrOH = 95:5, flow rate = 1.0 mL/min, 30 °C, wavelength = 254 nm, $t_R = 15.804$ min for major isomer, $t_R = 16.775$ min for minor isomer).



Signal: VWD1A, Wavelength=254 nm						Name
RT [min]	Type	Width [min]	Area	Height	Area%	
15.742	BV	1.49	3043.52	148.70	49.80	
16.707	VB	2.38	3067.44	143.30	50.20	
	Sum		6110.96			




Signal: VWD1A, Wavelength=254 nm						Name
RT [min]	Type	Width [min]	Area	Height	Area%	
15.804	BM m	0.32	1151.15	55.41	76.13	
16.775	MM m	0.34	360.97	16.59	23.87	
	Sum		1512.12			

9. Reference

- [1] Uyanik, M., Yasui, T. & Ishihara, K. Enantioselective Kita oxidative spirolactonization catalyzed by in situ generated chiral hypervalent iodine(III) species. *Angew. Chem. Int. Ed.* **49**, 2175–2177 (2010).
- [2] Uyanik, M., Yasui, T. & Ishihara, K. Chiral hypervalent organoiodine-catalyzed enantioselective oxidative spirolactonization of naphthol derivatives. *J. Org. Chem.* **82**, 11946–11953 (2010).
- [3] Jain, N., Xu, S. & Ciufolini, M. A. Asymmetric oxidative cycloetherification of naphtholic alcohols. *Chem. Eur. J.* **23**, 4542–4546 (2017).
- [4] Zhang, D.-Y., Xu, L., Wu, H. & Gong, L.-Z. Chiral iodine-catalyzed dearomatizative spirocyclization for the enantioselective construction of an all-carbon stereogenic center. *Chem. Eur. J.* **21**, 10314–10317 (2015).
- [5] Wu, H., He, Y.-P., Xu, L., Zhang, D.-Y. & Gong, L.-Z. Asymmetric organocatalytic direct C(sp²)-H/C(sp³)-H oxidative cross-coupling by chiral iodine reagent. *Angew. Chem. Int. Ed.* **53**, 3466–3469 (2014).
- [6] Pluta, R., Krach, P. E., Cavallo, L., Falivene, L. & Rueping, M. Metal-free catalytic asymmetric fluorination of keto esters using a combination of hydrogen fluoride (HF) and oxidant: experiment and computation. *ACS Catal.* **8**, 2582–2588 (2018).
- [7] Teiichi, M., Kiyotaka, F., Tadakazu, T., Kazuyoshi, Y. & Masazumi, N. Synthesis and biological properties of novel sphingosine derivatives. *Bioorg. Med. Chem. Lett.* **15**, 1115–1119 (2005).
- [8] Bower, J.F., Szeto, P. & Gallagher, T. Enantiopure 1,4-benzoxazines via 1,2-cyclic sulfamidates. Synthesis of levofloxacin. *Org. Lett.* **9**, 3283–3286 (2007).
- [9] Butler, E., Florentino, L., Cornut, D., Gomez-Campillos, G., Liu, H., Regan, A. C. & Thomas, E. J. Enantiopure 1,4-benzoxazines via 1,2-cyclic sulfamidates. Synthesis of macrocyclic precursors of the vioprolides. *Org. Biomol. Chem.* **16**, 6935–6960 (2018).

10. X-ray crystallography analysis

Cat-8 (CCDC 2236217)



checkCIF/PLATON report

Structure factors have been supplied for datablock(s) mo_230104_zhj_mes

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: mo_230104_zhj_mes

Bond precision:	C-C = 0.0042 Å	Wavelength=0.71073	
Cell:	a=13.3936 (3)	b=27.4740 (6)	c=9.5840 (2)
	alpha=90	beta=90	gamma=90
Temperature:	170 K		

	Calculated	Reported
Volume	3526.68 (13)	3526.68 (13)
Space group	P 21 21 2	P 21 21 2
Hall group	P 2 2ab	P 2 2ab
Moiety formula	C76 H81 I N4 O10 Si2	C76 H81 I N4 O10 Si2
Sum formula	C76 H81 I N4 O10 Si2	C76 H81 I N4 O10 Si2
Mr	1393.53	1393.52
Dx, g cm ⁻³	1.312	1.312
Z	2	2
Mu (mm ⁻¹)	0.549	0.549
F000	1452.0	1452.0
F000'	1451.95	
h, k, lmax	17, 35, 12	17, 35, 12
Nref	8135 [4559]	8123
Tmin, Tmax	0.810, 0.848	0.679, 0.746
Tmin'	0.768	

Correction method= # Reported T Limits: Tmin=0.679 Tmax=0.746
AbsCorr = MULTI-SCAN

Data completeness= 1.78/1.00 Theta (max)= 27.495

R(reflections)= 0.0245 (7539)	wR2 (reflections)= 0.0584 (8123)
S = 1.046	Npar= 470

The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.

Alert level C

PLAT220_ALERT_2_C	NonSolvent	Resd 1 C	Ueq(max)/Ueq(min)	Range	4.3	Ratio
PLAT222_ALERT_3_C	NonSolvent	Resd 1 H	Uiso(max)/Uiso(min)	Range	4.1	Ratio
PLAT911_ALERT_3_C	Missing FCF Refl	Between Thmin & STh/L=	0.600		3	Report

Alert level G


PLAT002_ALERT_2_G	Number of Distance or Angle Restraints on AtSite				13	Note
PLAT003_ALERT_2_G	Number of Uiso or Uij Restrained non-H Atoms ...				9	Report
PLAT007_ALERT_5_G	Number of Unrefined Donor-H Atoms				1	Report
PLAT176_ALERT_4_G	The CIF-Embedded .res File Contains SADI Records				15	Report
PLAT178_ALERT_4_G	The CIF-Embedded .res File Contains SIMU Records				1	Report
PLAT188_ALERT_3_G	A Non-default SIMU Restraint Value has been used				0.0200	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT191_ALERT_3_G	A Non-default SADI Restraint Value has been used				0.0400	Report
PLAT301_ALERT_3_G	Main Residue Disorder	(Resd 1)			13%	Note
PLAT791_ALERT_4_G	Model has Chirality at C5	(Sohnke SpGr)			R	Verify
PLAT791_ALERT_4_G	Model has Chirality at C12	(Sohnke SpGr)			S	Verify
PLAT860_ALERT_3_G	Number of Least-Squares Restraints				111	Note
PLAT910_ALERT_3_G	Missing # of FCF Reflection(s) Below Theta(Min).				2	Note
PLAT912_ALERT_4_G	Missing # of FCF Reflections Above STh/L=	0.600			1	Note
PLAT933_ALERT_2_G	Number of HKL-OMIT Records in Embedded .res File				3	Note
PLAT978_ALERT_2_G	Number C-C Bonds with Positive Residual Density.				9	Info

0 **ALERT level A** = Most likely a serious problem - resolve or explain
0 **ALERT level B** = A potentially serious problem, consider carefully
3 **ALERT level C** = Check. Ensure it is not caused by an omission or oversight
22 **ALERT level G** = General information/check it is not something unexpected

0 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
5 ALERT type 2 Indicator that the structure model may be wrong or deficient
14 ALERT type 3 Indicator that the structure quality may be low
5 ALERT type 4 Improvement, methodology, query or suggestion
1 ALERT type 5 Informative message, check

Supplementary Figure 5. Single-crystal X-ray crystallography of Cat-8

11 (CCDC 2236218)



checkCIF/PLATON report

Structure factors have been supplied for datablock(s) mo_230103_zhj_nh2_0m

THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED CRYSTALLOGRAPHIC REFEREE.

No syntax errors found. CIF dictionary Interpreting this report

Datablock: mo_230103_zhj_nh2_0m

Bond precision: C-C = 0.0087 Å Wavelength=0.71073
Cell: a=28.216 (9) b=13.252 (2) c=14.528 (3)
alpha=90 beta=90 gamma=90
Temperature: 170 K

	Calculated	Reported
Volume	5432 (2)	5432 (2)
Space group	P 21 21 2	P 21 21 2
Hall group	P 2 2ab	P 2 2ab
Moiety formula	C56 H60 I N4 O8 Si2	C56 H60 I N4 O8 Si2
Sum formula	C56 H60 I N4 O8 Si2	C56 H61 I N4 O8 Si2
Mr	1100.16	1101.16
Dx, g cm ⁻³	1.345	1.346
Z	4	4
Mu (mm ⁻¹)	0.690	0.690
F000	2276.0	2280.0
F000'	2275.63	
h, k, lmax	39, 18, 20	38, 18, 20
Nref	16096 [8799]	15884
Tmin, Tmax	0.767, 0.813	0.663, 0.746
Tmin'	0.718	

Correction method= # Reported T Limits: Tmin=0.663 Tmax=0.746
AbsCorr = MULTI-SCAN

Data completeness= 1.81/0.99 Theta (max)= 30.159

R(reflections)= 0.0439 (11790) wR2(reflections)=
S = 1.035 Npar= 811 0.1185 (15884)

The following ALERTS were generated. Each ALERT has the format
test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.

● **Alert level C**

PLAT041_ALERT_1_C	Calc. and Reported SumFormula	Strings Differ	Please Check
PLAT068_ALERT_1_C	Reported F000 Differs from Calcd (or Missing)...		Please Check
PLAT220_ALERT_2_C	NonSolvent Resd 1 C	Ueq(max)/Ueq(min) Range	3.5 Ratio
PLAT234_ALERT_4_C	Large Hirshfeld Difference	C17 --C18	0.17 Ang.
PLAT241_ALERT_2_C	High 'MainMol' Ueq as Compared to Neighbors of		C16 Check
PLAT241_ALERT_2_C	High 'MainMol' Ueq as Compared to Neighbors of		C18 Check
PLAT241_ALERT_2_C	High 'MainMol' Ueq as Compared to Neighbors of		C24 Check
PLAT241_ALERT_2_C	High 'MainMol' Ueq as Compared to Neighbors of		C47 Check
PLAT242_ALERT_2_C	Low 'MainMol' Ueq as Compared to Neighbors of		C10 Check
PLAT242_ALERT_2_C	Low 'MainMol' Ueq as Compared to Neighbors of		C14 Check
PLAT242_ALERT_2_C	Low 'MainMol' Ueq as Compared to Neighbors of		C35 Check
PLAT342_ALERT_3_C	Low Bond Precision on C-C Bonds		0.00868 Ang.
PLAT415_ALERT_2_C	Short Inter D-H..H-X	H1B ..H36C	2.05 Ang.
		x,y,l+z =	1_556 Check
PLAT420_ALERT_2_C	D-H Bond Without Acceptor	N1 --H1A	Please Check
PLAT420_ALERT_2_C	D-H Bond Without Acceptor	N1 --H1B	Please Check
PLAT420_ALERT_2_C	D-H Bond Without Acceptor	N3 --H3A	Please Check
PLAT420_ALERT_2_C	D-H Bond Without Acceptor	N3 --H3B	Please Check
PLAT934_ALERT_3_C	Number of (Iobs-Icalc)/Sigma(W) > 10 Outliers ..		1 Check
PLAT975_ALERT_2_C	Check Calcd Resid. Dens.	1.08Ang From C7	0.52 eA-3

● **Alert level G**

FORMU01_ALERT_1_G There is a discrepancy between the atom counts in the
_chemical_formula_sum and _chemical_formula_moiety. This is
usually due to the moiety formula being in the wrong format.
Atom count from _chemical_formula_sum: C56 H61 I1 N4 O8 Si2
Atom count from _chemical_formula_moiety:C56 H60 I1 N4 O8 Si2

FORMU01_ALERT_2_G There is a discrepancy between the atom counts in the
_chemical_formula_sum and the formula from the _atom_site* data.
Atom count from _chemical_formula_sum:C56 H61 I1 N4 O8 Si2
Atom count from the _atom_site data: C56 H60 I1 N4 O8 Si2


CELLZ01_ALERT_1_G Difference between formula and atom_site contents detected.
CELLZ01_ALERT_1_G WARNING: H atoms missing from atom site list. Is this intentional?
From the CIF: _cell_formula_units_Z 4
From the CIF: _chemical_formula_sum C56 H61 I N4 O8 Si2
TEST: Compare cell contents of formula and atom_site data

atom	Z*formula	cif sites	diff
C	224.00	224.00	0.00
H	244.00	240.00	4.00
I	4.00	4.00	0.00
N	16.00	16.00	0.00
O	32.00	32.00	0.00
Si	8.00	8.00	0.00


PLAT002_ALERT_2_G	Number of Distance or Angle Restraints on AtSite	40	Note
PLAT003_ALERT_2_G	Number of Uiso or Uij Restrained non-H Atoms ...	39	Report
PLAT007_ALERT_5_G	Number of Unrefined Donor-H Atoms	4	Report
PLAT172_ALERT_4_G	The CIF-Embedded .res File Contains DFIX Records	1	Report
PLAT176_ALERT_4_G	The CIF-Embedded .res File Contains SADI Records	44	Report

11. ^1H , ^{13}C , ^{19}F spectrum of compounds


11.1 NMR spectra of intermediates and catalyst




Supplementary Figure 7. ^1H NMR Spectrum of **9** (400 MHz, CDCl_3)




Supplementary Figure 8. ^{13}C NMR Spectrum of **9** (100 MHz, CDCl_3)




Supplementary Figure 9. ¹H NMR Spectrum of **10** (400 MHz, CDCl₃)




Supplementary Figure 10. ¹³C NMR Spectrum of **10** (100 MHz, CDCl₃)




Supplementary Figure 11. ¹H NMR Spectrum of **11** (400 MHz, CDCl₃)




Supplementary Figure 12. ¹³C NMR Spectrum of **11** (100 MHz, CDCl₃)




Supplementary Figure 13. ¹H NMR Spectrum of SI-13 (400 MHz, CDCl₃)




Supplementary Figure 14. ¹³C NMR Spectrum of SI-13 (100 MHz, CDCl₃)




Supplementary Figure 15. ^1H NMR Spectrum of **Cat-1** (400 MHz, CDCl_3)




Supplementary Figure 16. ^{13}C NMR Spectrum of **Cat-1** (100 MHz, CDCl_3)




Supplementary Figure 17. ^1H NMR Spectrum of **Cat-2** (400 MHz, CDCl_3)




Supplementary Figure 18. ^{13}C NMR Spectrum of **Cat-2** (100 MHz, CDCl_3)




Supplementary Figure 19. ^1H NMR Spectrum of **Cat-3** (400 MHz, CDCl_3)




Supplementary Figure 20. ^{13}C NMR Spectrum of **Cat-3** (100 MHz, CDCl_3)




Supplementary Figure 21. ¹H NMR Spectrum of **Cat-4** (400 MHz, CDCl₃)




Supplementary Figure 22. ¹³C NMR Spectrum of **Cat-4** (100 MHz, CDCl₃)




Supplementary Figure 23. ^1H NMR Spectrum of **Cat-5** (400 MHz, CDCl_3)




Supplementary Figure 24. ^{13}C NMR Spectrum of **Cat-5** (100 MHz, CDCl_3)




Supplementary Figure 25. ^1H NMR Spectrum of **Cat-6** (400 MHz, CDCl_3)




Supplementary Figure 26. ^{13}C NMR Spectrum of **Cat-6** (100 MHz, CDCl_3)




Supplementary Figure 27. ¹H NMR Spectrum of Cat-7 (400 MHz, CDCl₃)




Supplementary Figure 28. ¹³C NMR Spectrum of Cat-7 (100 MHz, CDCl₃)




Supplementary Figure 29. ^{19}F NMR Spectrum of **Cat-7** (376 MHz, CDCl_3)




Supplementary Figure 30. ^1H NMR Spectrum of **Cat-8** (400 MHz, CDCl_3)




Supplementary Figure 31. ^{13}C NMR Spectrum of **Cat-8** (100 MHz, CDCl_3)




Supplementary Figure 32. ^1H NMR Spectrum of **Cat-9** (400 MHz, CDCl_3)




Supplementary Figure 33. ^{13}C NMR Spectrum of **Cat-9** (100 MHz, CDCl_3)




Supplementary Figure 34. ^1H NMR Spectrum of **Cat-10** (400 MHz, CDCl_3)




Supplementary Figure 35. ^{13}C NMR Spectrum of **Cat-10** (100 MHz, CDCl_3)




Supplementary Figure 36. ^1H NMR Spectrum of **Cat-11** (400 MHz, CDCl_3)




Supplementary Figure 37. ^{13}C NMR Spectrum of **Cat-11** (100 MHz, CDCl_3)




Supplementary Figure 38. ^1H NMR Spectrum of **Cat-12** (400 MHz, CDCl_3)




Supplementary Figure 39. ^{13}C NMR Spectrum of **Cat-12** (100 MHz, CDCl_3)




Supplementary Figure 40. ^1H NMR Spectrum of **Cat-13** (400 MHz, CDCl_3)




Supplementary Figure 41. ^{13}C NMR Spectrum of **Cat-13** (100 MHz, CDCl_3)




Supplementary Figure 42. ^1H NMR Spectrum of **Cat-14** (400 MHz, CDCl_3)




Supplementary Figure 43. ¹³C NMR Spectrum of **Cat-14** (100 MHz, CDCl₃)




Supplementary Figure 44. ¹H NMR Spectrum of **Cat-15** (400 MHz, CDCl₃)




Supplementary Figure 45. ¹³C NMR Spectrum of **Cat-15** (100 MHz, CDCl₃)




Supplementary Figure 46. ¹⁹F NMR Spectrum of **Cat-15** (376 MHz, CDCl₃)




Supplementary Figure 47. ¹H NMR Spectrum of **Cat-16** (400 MHz, CDCl₃)




Supplementary Figure 48. ¹³C NMR Spectrum of **Cat-16** (100 MHz, CDCl₃)




Supplementary Figure 49. ¹H NMR Spectrum of **Cat-17** (400 MHz, CDCl₃)




Supplementary Figure 50. ¹³C NMR Spectrum of **Cat-17** (100 MHz, CDCl₃)




Supplementary Figure 51. ^1H NMR Spectrum of Cat-18 (400 MHz, CDCl_3)




Supplementary Figure 52. ^{13}C NMR Spectrum of Cat-18 (100 MHz, CDCl_3)




Supplementary Figure 53. ^{19}F NMR Spectrum of **Cat-18** (376 MHz, CDCl_3)




Supplementary Figure 54. ^1H NMR Spectrum of **Cat-19** (400 MHz, CDCl_3)




Supplementary Figure 55. ^{13}C NMR Spectrum of **Cat-19** (100 MHz, CDCl_3)




Supplementary Figure 56. ^1H NMR Spectrum of **Cat-20** (400 MHz, CDCl_3)




Supplementary Figure 57. ^{13}C NMR Spectrum of **Cat-20** (100 MHz, CDCl_3)




Supplementary Figure 58. ^1H NMR Spectrum of **Cat-21** (400 MHz, CDCl_3)




Supplementary Figure 59. ^{13}C NMR Spectrum of **Cat-21** (100 MHz, CDCl_3)




Supplementary Figure 60. ^1H NMR Spectrum of **Cat-25** (400 MHz, CDCl_3)




Supplementary Figure 61. ^{13}C NMR Spectrum of **Cat-25** (100 MHz, CDCl_3)




Supplementary Figure 62. ^1H NMR Spectrum of **Cat-26** (400 MHz, CDCl_3)




Supplementary Figure 63. ¹³C NMR Spectrum of **Cat-26** (100 MHz, CDCl₃)




Supplementary Figure 64. ¹H NMR Spectrum of **Cat-27** (400 MHz, CDCl₃)




Supplementary Figure 65. ¹³C NMR Spectrum of **Cat-27** (100 MHz, CDCl₃)




Supplementary Figure 66. ¹⁹F NMR Spectrum of **Cat-27** (376 MHz, CDCl₃)




Supplementary Figure 67. ^1H NMR Spectrum of **Cat-28** (400 MHz, CDCl_3)




Supplementary Figure 68. ^{13}C NMR Spectrum of **Cat-28** (100 MHz, CDCl_3)




Supplementary Figure 69. ¹H NMR Spectrum of Cat-29 (400 MHz, CDCl₃)




Supplementary Figure 70. ¹³C NMR Spectrum of Cat-29 (100 MHz, CDCl₃)




Supplementary Figure 71. ¹H NMR Spectrum of **Cat-30** (400 MHz, CDCl₃)




Supplementary Figure 72. ¹³C NMR Spectrum of **Cat-30** (100 MHz, CDCl₃)




Supplementary Figure 73. ¹H NMR Spectrum of **Cat-31** (400 MHz, CDCl₃)




Supplementary Figure 74. ¹³C NMR Spectrum of **Cat-31** (100 MHz, CDCl₃)




Supplementary Figure 75. ^1H NMR Spectrum of **Cat-32** (400 MHz, CDCl_3)




Supplementary Figure 76. ^{13}C NMR Spectrum of **Cat-32** (100 MHz, CDCl_3)




Supplementary Figure 77. ¹H NMR Spectrum of **Cat-33** (400 MHz, CDCl₃)




Supplementary Figure 78. ¹³C NMR Spectrum of **Cat-33** (100 MHz, CDCl₃)




Supplementary Figure 79. ^1H NMR Spectrum of **Cat-34** (400 MHz, CDCl_3)




Supplementary Figure 80. ^{13}C NMR Spectrum of **Cat-34** (100 MHz, CDCl_3)




Supplementary Figure 81. ¹H NMR Spectrum of **Cat-35** (400 MHz, CDCl₃)




Supplementary Figure 82. ¹³C NMR Spectrum of **Cat-35** (100 MHz, CDCl₃)




Supplementary Figure 83. ^1H NMR Spectrum of **Cat-36** (400 MHz, CDCl_3)




Supplementary Figure 84. ^{13}C NMR Spectrum of **Cat-36** (100 MHz, CDCl_3)




Supplementary Figure 85. ¹H NMR Spectrum of **Cat-37** (400 MHz, CDCl₃)




Supplementary Figure 86. ¹³C NMR Spectrum of **Cat-37** (100 MHz, CDCl₃)




Supplementary Figure 87. ¹H NMR Spectrum of Cat-38 (400 MHz, CDCl₃)




Supplementary Figure 88. ¹³C NMR Spectrum of Cat-38 (100 MHz, CDCl₃)




Supplementary Figure 89. ^1H NMR Spectrum of **Cat-39** (400 MHz, CDCl_3)




Supplementary Figure 90. ^{13}C NMR Spectrum of **Cat-39** (100 MHz, CDCl_3)




Supplementary Figure 91. ¹H NMR Spectrum of **Cat-40** (400 MHz, CDCl₃)




Supplementary Figure 92. ¹³C NMR Spectrum of **Cat-40** (100 MHz, CDCl₃)




Supplementary Figure 93. ¹H NMR Spectrum of **Cat-41** (400 MHz, CDCl₃)




Supplementary Figure 94. ¹³C NMR Spectrum of **Cat-41** (100 MHz, CDCl₃)




Supplementary Figure 95. ^1H NMR Spectrum of **Cat-43** (400 MHz, CDCl_3)




Supplementary Figure 96. ^{13}C NMR Spectrum of **Cat-43** (100 MHz, CDCl_3)




Supplementary Figure 97. ^1H NMR Spectrum of **Cat-45** (400 MHz, CDCl_3)




Supplementary Figure 98. ^{13}C NMR Spectrum of **Cat-45** (100 MHz, CDCl_3)




Supplementary Figure 99. ^1H NMR Spectrum of **Cat-47** (400 MHz, CDCl_3)




Supplementary Figure 100. ^{13}C NMR Spectrum of **Cat-47** (100 MHz, CDCl_3)




Supplementary Figure 101. ^1H NMR Spectrum of Cat-48 (400 MHz, CDCl_3)



Supplementary Figure 102. ^{13}C NMR Spectrum of Cat-48 (100 MHz, CDCl_3)




Supplementary Figure 103. ^1H NMR Spectrum of **Cat-49** (400 MHz, CDCl_3)




Supplementary Figure 104. ^{13}C NMR Spectrum of **Cat-49** (100 MHz, CDCl_3)

11.2 NMR spectra of product


11.2.1 Spectrum of enantioselective oxidative dearomatization




Supplementary Figure 105. ^1H NMR Spectrum of **13a** (400 MHz, CDCl_3)




Supplementary Figure 106. ^{13}C NMR Spectrum of **13a** (100 MHz, CDCl_3)




Supplementary Figure 107. ¹H NMR Spectrum of **13b** (400 MHz, CDCl₃)




Supplementary Figure 108. ¹³C NMR Spectrum of **13b** (100 MHz, CDCl₃)




Supplementary Figure 109. ¹H NMR Spectrum of **13c** (400 MHz, CDCl₃)




Supplementary Figure 110. ¹³C NMR Spectrum of **13c** (100 MHz, CDCl₃)




Supplementary Figure 111. ¹H NMR Spectrum of **13d** (400 MHz, CDCl₃)




Supplementary Figure 112. ¹³C NMR Spectrum of **13d** (100 MHz, CDCl₃)




Supplementary Figure 113. ¹H NMR Spectrum of **13e** (400 MHz, CDCl₃)




Supplementary Figure 114. ¹³C NMR Spectrum of **13e** (100 MHz, CDCl₃)




Supplementary Figure 115. ^1H NMR Spectrum of **13f** (400 MHz, CDCl_3)




Supplementary Figure 116. ^{13}C NMR Spectrum of **13f** (100 MHz, CDCl_3)




Supplementary Figure 117. ^1H NMR Spectrum of **13g** (400 MHz, CDCl_3)




Supplementary Figure 118. ^{13}C NMR Spectrum of **13g** (100 MHz, CDCl_3)




Supplementary Figure 119. ¹H NMR Spectrum of **13h** (400 MHz, CDCl₃)




Supplementary Figure 120. ¹³C NMR Spectrum of **13h** (100 MHz, CDCl₃)




Supplementary Figure 121. ¹H NMR Spectrum of 13i (400 MHz, CDCl₃)




Supplementary Figure 122. ¹³C NMR Spectrum of 13i (100 MHz, CDCl₃)




Supplementary Figure 123. ^1H NMR Spectrum of **13j** (400 MHz, CDCl_3)




Supplementary Figure 124. ^{13}C NMR Spectrum of **13j** (100 MHz, CDCl_3)




Supplementary Figure 125. ^1H NMR Spectrum of **13k** (400 MHz, CDCl_3)




Supplementary Figure 126. ^{13}C NMR Spectrum of **13k** (100 MHz, CDCl_3)




Supplementary Figure 127. ¹H NMR Spectrum of 131 (400 MHz, CDCl₃)




Supplementary Figure 128. ¹³C NMR Spectrum of 131 (100 MHz, CDCl₃)




Supplementary Figure 129. ¹H NMR Spectrum of 13m (400 MHz, CDCl₃)




Supplementary Figure 130. ¹³C NMR Spectrum of 13m (100 MHz, CDCl₃)




Supplementary Figure 131. ¹H NMR Spectrum of **13n** (400 MHz, CDCl₃)




Supplementary Figure 132. ¹³C NMR Spectrum of **13n** (100 MHz, CDCl₃)




Supplementary Figure 133. ^1H NMR Spectrum of **13o** (400 MHz, CDCl_3)




Supplementary Figure 134. ^{13}C NMR Spectrum of **13o** (100 MHz, CDCl_3)




Supplementary Figure 135. ^1H NMR Spectrum of **14a** (400 MHz, CDCl_3)




Supplementary Figure 136. ^{13}C NMR Spectrum of **14a** (100 MHz, CDCl_3)




Supplementary Figure 137. ¹H NMR Spectrum of 14b (400 MHz, CDCl₃)




Supplementary Figure 138. ¹³C NMR Spectrum of 14b (100 MHz, CDCl₃)




Supplementary Figure 139. ^1H NMR Spectrum of **14c** (400 MHz, CDCl_3)




Supplementary Figure 140. ^{13}C NMR Spectrum of **14c** (100 MHz, CDCl_3)




Supplementary Figure 141. ^1H NMR Spectrum of **14d** (400 MHz, CDCl_3)




Supplementary Figure 142. ^{13}C NMR Spectrum of **14d** (100 MHz, CDCl_3)




Supplementary Figure 143. ^1H NMR Spectrum of **14e** (400 MHz, CDCl_3)




Supplementary Figure 144. ^{13}C NMR Spectrum of **14e** (100 MHz, CDCl_3)




Supplementary Figure 145. ^1H NMR Spectrum of **14f** (400 MHz, CDCl_3)




Supplementary Figure 146. ^{13}C NMR Spectrum of **14f** (100 MHz, CDCl_3)




Supplementary Figure 147. ^1H NMR Spectrum of **14g** (400 MHz, CDCl_3)




Supplementary Figure 148. ^{13}C NMR Spectrum of **14g** (100 MHz, CDCl_3)




Supplementary Figure 149. ^1H NMR Spectrum of **14h** (400 MHz, CDCl_3)




Supplementary Figure 150. ^{13}C NMR Spectrum of **14h** (100 MHz, CDCl_3)




Supplementary Figure 151. ¹H NMR Spectrum of **14i** (400 MHz, CDCl₃)



Supplementary Figure 152. ¹³C NMR Spectrum of **14i** (100 MHz, CDCl₃)




Supplementary Figure 153. ^1H NMR Spectrum of **14j** (400 MHz, CDCl_3)




Supplementary Figure 154. ^{13}C NMR Spectrum of **14j** (100 MHz, CDCl_3)


11.2.2 Spectrum of oxidative spirolactonization




Supplementary Figure 155. ^1H NMR Spectrum of **16a** (400 MHz, CDCl_3)




Supplementary Figure 156. ^{13}C NMR Spectrum of **16a** (100 MHz, CDCl_3)




Supplementary Figure 157. ¹H NMR Spectrum of **16b** (400 MHz, CDCl₃)




Supplementary Figure 158. ¹³C NMR Spectrum of **16b** (100 MHz, CDCl₃)




Supplementary Figure 159. ¹H NMR Spectrum of **16c** (400 MHz, CDCl₃)




Supplementary Figure 160. ¹³C NMR Spectrum of **16c** (100 MHz, CDCl₃)




Supplementary Figure 163. ¹H NMR Spectrum of **16e** (400 MHz, CDCl₃)



Supplementary Figure 164. ¹³C NMR Spectrum of **16e** (100 MHz, CDCl₃)




Supplementary Figure 165. ¹H NMR Spectrum of 16f (400 MHz, CDCl₃)




Supplementary Figure 166. ¹³C NMR Spectrum of 16f (100 MHz, CDCl₃)


11.2.3 Spectrum of direct C(sp²)-H/C(sp³)-H cross-coupling




Supplementary Figure 167. ¹H NMR Spectrum of **18a** (400 MHz, CDCl₃)




Supplementary Figure 168. ¹³C NMR Spectrum of **18a** (100 MHz, CDCl₃)




Supplementary Figure 169. ^1H NMR Spectrum of **18b** (400 MHz, CDCl_3)




Supplementary Figure 170. ^{13}C NMR Spectrum of **18b** (100 MHz, CDCl_3)




Supplementary Figure 171. ¹H NMR Spectrum of **18c** (400 MHz, CDCl₃)




Supplementary Figure 172. ¹³C NMR Spectrum of **18c** (100 MHz, CDCl₃)




Supplementary Figure 173. ¹H NMR Spectrum of **18d** (400 MHz, CDCl₃)




Supplementary Figure 174. ¹³C NMR Spectrum of **18d** (100 MHz, CDCl₃)




Supplementary Figure 175. ¹H NMR Spectrum of **18e** (400 MHz, CDCl₃)



Supplementary Figure 176. ¹³C NMR Spectrum of **18e** (100 MHz, CDCl₃)




Supplementary Figure 177. ¹H NMR Spectrum of 18f (400 MHz, CDCl₃)




Supplementary Figure 178. ¹³C NMR Spectrum of 18f (100 MHz, CDCl₃)


11.2.4 Spectrum of oxidative fluorination of keto esters




Supplementary Figure 179. ^1H NMR Spectrum of **20a** (400 MHz, CDCl_3)




Supplementary Figure 180. ^{13}C NMR Spectrum of **20a** (100 MHz, CDCl_3)




Supplementary Figure 181. ¹⁹F NMR Spectrum of **20a** (376 MHz, CDCl₃)




Supplementary Figure 182. ¹H NMR Spectrum of **20b** (400 MHz, CDCl₃)




Supplementary Figure 183. ^{13}C NMR Spectrum of **20b** (100 MHz, CDCl_3)




Supplementary Figure 184. ^{19}F NMR Spectrum of **20b** (376 MHz, CDCl_3)




Supplementary Figure 185. ¹H NMR Spectrum of **20c** (400 MHz, CDCl₃)




Supplementary Figure 186. ¹³C NMR Spectrum of **20c** (100 MHz, CDCl₃)




Supplementary Figure 187. ^{19}F NMR Spectrum of **20c** (376 MHz, CDCl_3)




Supplementary Figure 188. ^1H NMR Spectrum of **20d** (400 MHz, CDCl_3)




Supplementary Figure 189. ^{13}C NMR Spectrum of **20d** (100 MHz, CDCl_3)




Supplementary Figure 190. ^{19}F NMR Spectrum of **20d** (376 MHz, CDCl_3)




Supplementary Figure 191. ¹H NMR Spectrum of **20e** (400 MHz, CDCl₃)




Supplementary Figure 192. ¹³C NMR Spectrum of **20e** (100 MHz, CDCl₃)




Supplementary Figure 193. ¹⁹F NMR Spectrum of **20e** (376 MHz, CDCl₃)




Supplementary Figure 194. ¹H NMR Spectrum of **20f** (400 MHz, CDCl₃)




Supplementary Figure 195. ^{13}C NMR Spectrum of **20f** (100 MHz, CDCl_3)




Supplementary Figure 196. ^{19}F NMR Spectrum of **20f** (376 MHz, CDCl_3)




Supplementary Figure 197. ¹H NMR Spectrum of **20g** (400 MHz, CDCl₃)




Supplementary Figure 198. ¹³C NMR Spectrum of **20g** (100 MHz, CDCl₃)




Supplementary Figure 199. ^{19}F NMR Spectrum of **20g** (376 MHz, CDCl_3)




Supplementary Figure 200. ^1H NMR Spectrum of **20h** (400 MHz, CDCl_3)




Supplementary Figure 201. ^{13}C NMR Spectrum of **20h** (100 MHz, CDCl_3)




Supplementary Figure 202. ^{19}F NMR Spectrum of **20h** (376 MHz, CDCl_3)




Supplementary Figure 203. ¹H NMR Spectrum of **20i** (400 MHz, CDCl₃)




Supplementary Figure 204. ¹³C NMR Spectrum of **20i** (100 MHz, CDCl₃)




Supplementary Figure 205. ^{19}F NMR Spectrum of **20i** (376 MHz, CDCl_3)




Supplementary Figure 206. ^1H NMR Spectrum of **20j** (400 MHz, CDCl_3)




Supplementary Figure 207. ^{13}C NMR Spectrum of **20j** (100 MHz, CDCl_3)





Supplementary Figure 208. ^{19}F NMR Spectrum of **20j** (376 MHz, CDCl_3)



Supplementary Figure 209. ^1H NMR Spectrum of **20k** (400 MHz, CDCl_3)



Supplementary Figure 210. ^{13}C NMR Spectrum of **20k** (100 MHz, CDCl_3)



Supplementary Figure 211. ^{19}F NMR Spectrum of **20i** (376 MHz, CDCl_3)